NZ710447B2 - Fluorinated integrin antagonists - Google Patents
Fluorinated integrin antagonists Download PDFInfo
- Publication number
- NZ710447B2 NZ710447B2 NZ710447A NZ71044714A NZ710447B2 NZ 710447 B2 NZ710447 B2 NZ 710447B2 NZ 710447 A NZ710447 A NZ 710447A NZ 71044714 A NZ71044714 A NZ 71044714A NZ 710447 B2 NZ710447 B2 NZ 710447B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- mmol
- compounds
- equiv
- solvate
- Prior art date
Links
- 102000006495 integrins Human genes 0.000 title claims description 53
- 108010044426 integrins Proteins 0.000 title claims description 51
- 230000003042 antagnostic Effects 0.000 title claims description 23
- 239000005557 antagonist Substances 0.000 title claims description 23
- 150000001875 compounds Chemical class 0.000 claims abstract description 281
- 206010012689 Diabetic retinopathy Diseases 0.000 claims abstract description 39
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 29
- 208000001344 Macular Edema Diseases 0.000 claims abstract description 25
- 206010025415 Macular oedema Diseases 0.000 claims abstract description 25
- 201000010230 macular retinal edema Diseases 0.000 claims abstract description 25
- 208000004644 Retinal Vein Occlusion Diseases 0.000 claims abstract description 24
- 239000000203 mixture Substances 0.000 claims description 107
- 239000011780 sodium chloride Substances 0.000 claims description 73
- 201000010099 disease Diseases 0.000 claims description 70
- 150000003839 salts Chemical class 0.000 claims description 60
- 239000003795 chemical substances by application Substances 0.000 claims description 43
- 230000002401 inhibitory effect Effects 0.000 claims description 39
- 239000003814 drug Substances 0.000 claims description 36
- 239000012453 solvate Substances 0.000 claims description 35
- 239000003112 inhibitor Substances 0.000 claims description 33
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 27
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 27
- 125000001153 fluoro group Chemical group F* 0.000 claims description 23
- 229910052757 nitrogen Inorganic materials 0.000 claims description 23
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 21
- 238000002560 therapeutic procedure Methods 0.000 claims description 17
- 230000001404 mediated Effects 0.000 claims description 12
- 229910052731 fluorine Inorganic materials 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 9
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 9
- 230000001028 anti-proliferant Effects 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- 239000003102 growth factor Substances 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 210000002950 fibroblast Anatomy 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 230000001472 cytotoxic Effects 0.000 claims description 5
- 231100000433 cytotoxic Toxicity 0.000 claims description 5
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 102100004109 HEY1 Human genes 0.000 claims description 4
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims description 4
- 101710037124 TEK Proteins 0.000 claims description 4
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 239000000546 pharmaceutic aid Substances 0.000 claims description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 3
- 125000004011 3 membered carbocyclic group Chemical group 0.000 claims description 3
- 125000001845 4 membered carbocyclic group Chemical group 0.000 claims description 3
- 125000004429 atoms Chemical group 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- 108010042918 Integrin alpha5beta1 Proteins 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 101710030892 FLT1 Proteins 0.000 claims 1
- 108091000081 Phosphotransferases Proteins 0.000 claims 1
- 102000030951 Phosphotransferases Human genes 0.000 claims 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 claims 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims 1
- 208000002780 Macular Degeneration Diseases 0.000 abstract description 34
- 206010012688 Diabetic retinal oedema Diseases 0.000 abstract description 25
- 201000011190 diabetic macular edema Diseases 0.000 abstract description 25
- 230000002194 synthesizing Effects 0.000 abstract description 20
- -1 AMD and DR Chemical class 0.000 description 124
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 122
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 88
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 72
- 235000002639 sodium chloride Nutrition 0.000 description 63
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 56
- 230000035492 administration Effects 0.000 description 52
- 239000011541 reaction mixture Substances 0.000 description 46
- 235000019439 ethyl acetate Nutrition 0.000 description 44
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 42
- 150000002500 ions Chemical class 0.000 description 38
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 38
- 239000000243 solution Substances 0.000 description 37
- 239000000741 silica gel Substances 0.000 description 36
- 229910002027 silica gel Inorganic materials 0.000 description 36
- 210000001508 Eye Anatomy 0.000 description 34
- 238000003756 stirring Methods 0.000 description 34
- 238000005160 1H NMR spectroscopy Methods 0.000 description 33
- 238000004440 column chromatography Methods 0.000 description 32
- 239000000706 filtrate Substances 0.000 description 32
- 230000000699 topical Effects 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- 229940079593 drugs Drugs 0.000 description 27
- 206010064930 Age-related macular degeneration Diseases 0.000 description 26
- 102100015249 VEGFA Human genes 0.000 description 26
- HEDRZPFGACZZDS-MICDWDOJSA-N deuterated chloroform Substances [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 26
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 25
- 238000009472 formulation Methods 0.000 description 24
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 23
- 229920000858 Cyclodextrin Polymers 0.000 description 22
- 230000015572 biosynthetic process Effects 0.000 description 22
- 229910052805 deuterium Inorganic materials 0.000 description 22
- 101700067048 CDC13 Proteins 0.000 description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 20
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 19
- 238000003786 synthesis reaction Methods 0.000 description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 229920001451 Polypropylene glycol Polymers 0.000 description 18
- 239000002253 acid Substances 0.000 description 18
- 210000004027 cells Anatomy 0.000 description 18
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 18
- 239000008079 hexane Substances 0.000 description 18
- 210000001525 Retina Anatomy 0.000 description 17
- 230000002829 reduced Effects 0.000 description 17
- 230000033115 angiogenesis Effects 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 16
- 239000007858 starting material Substances 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 14
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- 235000019341 magnesium sulphate Nutrition 0.000 description 14
- 229920001983 poloxamer Polymers 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- 238000004293 19F NMR spectroscopy Methods 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 13
- 230000002708 enhancing Effects 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 13
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M Lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 12
- 238000004166 bioassay Methods 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 210000002381 Plasma Anatomy 0.000 description 11
- 102100009661 VTN Human genes 0.000 description 11
- 108010031318 Vitronectin Proteins 0.000 description 11
- 239000012267 brine Substances 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 239000006188 syrup Substances 0.000 description 11
- 235000020357 syrup Nutrition 0.000 description 11
- 210000001519 tissues Anatomy 0.000 description 11
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 10
- 210000004204 Blood Vessels Anatomy 0.000 description 10
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- ZTHQBROSBNNGPU-UHFFFAOYSA-N butyl hydrogen sulfate Chemical compound CCCCOS(O)(=O)=O ZTHQBROSBNNGPU-UHFFFAOYSA-N 0.000 description 9
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 9
- 238000010348 incorporation Methods 0.000 description 9
- 239000002105 nanoparticle Substances 0.000 description 9
- 229920001992 poloxamer 407 Polymers 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Substances [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 9
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 8
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 8
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 8
- 108010062724 Ranibizumab Proteins 0.000 description 8
- 229960003876 Ranibizumab Drugs 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 230000001413 cellular Effects 0.000 description 8
- 239000000594 mannitol Substances 0.000 description 8
- 235000010355 mannitol Nutrition 0.000 description 8
- 239000002353 niosome Substances 0.000 description 8
- 229920001888 polyacrylic acid Polymers 0.000 description 8
- 230000002335 preservative Effects 0.000 description 8
- 239000003755 preservative agent Substances 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- KOVGKRYLVVJEJS-FNORWQNLSA-N tert-butyl (E)-3-[6-(difluoromethoxy)pyridin-3-yl]prop-2-enoate Chemical compound CC(C)(C)OC(=O)\C=C\C1=CC=C(OC(F)F)N=C1 KOVGKRYLVVJEJS-FNORWQNLSA-N 0.000 description 8
- WHGYBXFWUBPSRW-FOUAGVGXSA-N β-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 8
- 210000003711 Chorioallantoic Membrane Anatomy 0.000 description 7
- 229960001484 Edetic Acid Drugs 0.000 description 7
- 108050007372 Fibroblast growth factor family Proteins 0.000 description 7
- 102000018233 Fibroblast growth factor family Human genes 0.000 description 7
- 102000003993 Phosphatidylinositol 3-Kinases Human genes 0.000 description 7
- 108090000430 Phosphatidylinositol 3-Kinases Proteins 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 7
- 238000007792 addition Methods 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 239000002738 chelating agent Substances 0.000 description 7
- 238000009826 distribution Methods 0.000 description 7
- 239000000017 hydrogel Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000000375 suspending agent Substances 0.000 description 7
- 239000000080 wetting agent Substances 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- OZAIFHULBGXAKX-VAWYXSNFSA-N Azobisisobutyronitrile Chemical compound N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 6
- KGBXLFKZBHKPEV-UHFFFAOYSA-N Boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 150000001336 alkenes Chemical class 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 239000008135 aqueous vehicle Substances 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 239000004327 boric acid Substances 0.000 description 6
- 239000004359 castor oil Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000003889 eye drop Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 150000004677 hydrates Chemical class 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- HPQVWDOOUQVBTO-UHFFFAOYSA-N lithium aluminium hydride Substances [Li+].[Al-] HPQVWDOOUQVBTO-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000004530 micro-emulsion Substances 0.000 description 6
- 239000006070 nanosuspension Substances 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 229920002395 Aptamer Polymers 0.000 description 5
- 210000002889 Endothelial Cells Anatomy 0.000 description 5
- 229910010084 LiAlH4 Inorganic materials 0.000 description 5
- FBUKVWPVBMHYJY-UHFFFAOYSA-N Nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 5
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 5
- 229940035295 Ting Drugs 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 229920001400 block copolymer Polymers 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- HDQDUBPEBVXIBJ-UHFFFAOYSA-N hept-1-en-1-ol Chemical compound CCCCCC=CO HDQDUBPEBVXIBJ-UHFFFAOYSA-N 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrugs Drugs 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 230000002207 retinal Effects 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 210000001742 Aqueous Humor Anatomy 0.000 description 4
- 210000004369 Blood Anatomy 0.000 description 4
- 210000001772 Blood Platelets Anatomy 0.000 description 4
- 206010025421 Macule Diseases 0.000 description 4
- 229940044476 Poloxamer 407 Drugs 0.000 description 4
- 229940068965 Polysorbates Drugs 0.000 description 4
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 4
- JNYAEWCLZODPBN-CTQIIAAMSA-N Sorbitan Chemical class OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 4
- 210000004127 Vitreous Body Anatomy 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003618 borate buffered saline Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- OKKJLVBELUTLKV-MZCSYVLQSA-N cd3od Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- 150000001975 deuterium Chemical group 0.000 description 4
- LVSJLTMNAQBTPE-UHFFFAOYSA-N disodium tetraborate Chemical compound [Na+].[Na+].O1B(O)O[B-]2(O)OB(O)O[B-]1(O)O2 LVSJLTMNAQBTPE-UHFFFAOYSA-N 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 230000003511 endothelial Effects 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 125000003566 oxetanyl group Chemical group 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- NJRWNWYFPOFDFN-UHFFFAOYSA-L phosphonate(2-) Chemical compound [O-][P]([O-])=O NJRWNWYFPOFDFN-UHFFFAOYSA-L 0.000 description 4
- 230000000649 photocoagulation Effects 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 230000001023 pro-angiogenic Effects 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- 239000011604 retinal Substances 0.000 description 4
- 235000010339 sodium tetraborate Nutrition 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 239000003039 volatile agent Substances 0.000 description 4
- ZCZVGQCBSJLDDS-UHFFFAOYSA-N 1,2,3,4-tetrahydro-1,8-naphthyridine Chemical compound C1=CC=C2CCCNC2=N1 ZCZVGQCBSJLDDS-UHFFFAOYSA-N 0.000 description 3
- KJMXMUWEGVNEFC-UHFFFAOYSA-N 1-dimethoxyphosphoryl-6-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)hexan-2-one Chemical compound C1CCNC2=NC(CCCCC(=O)CP(=O)(OC)OC)=CC=C21 KJMXMUWEGVNEFC-UHFFFAOYSA-N 0.000 description 3
- OYLCUJRJCUXQBQ-UHFFFAOYSA-N 1-hepten-3-one Chemical compound CCCCC(=O)C=C OYLCUJRJCUXQBQ-UHFFFAOYSA-N 0.000 description 3
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- FKNRBROHCGKPPE-UHFFFAOYSA-N 9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)-3-[7-(trifluoromethyl)quinolin-3-yl]nonanoic acid Chemical compound C1=C(C(F)(F)F)C=CC2=CC(C(CCCCCCC=3N=C4NCCCC4=CC=3)CC(=O)O)=CN=C21 FKNRBROHCGKPPE-UHFFFAOYSA-N 0.000 description 3
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 3
- 230000036912 Bioavailability Effects 0.000 description 3
- 208000006386 Bone Resorption Diseases 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 229940012356 Eye Drops Drugs 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 206010029113 Neovascularisation Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 229940067631 Phospholipids Drugs 0.000 description 3
- 229920002415 Pluronic P-123 Polymers 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 208000007135 Retinal Neovascularization Diseases 0.000 description 3
- 210000001957 Retinal Vein Anatomy 0.000 description 3
- 206010038932 Retinopathy Diseases 0.000 description 3
- 206010038923 Retinopathy Diseases 0.000 description 3
- 229940075582 Sorbic Acid Drugs 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 3
- 238000002583 angiography Methods 0.000 description 3
- 230000001772 anti-angiogenic Effects 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 230000035514 bioavailability Effects 0.000 description 3
- 230000024279 bone resorption Effects 0.000 description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 230000000875 corresponding Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 150000002194 fatty esters Chemical class 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 3
- 230000002209 hydrophobic Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000003000 nontoxic Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000003287 optical Effects 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 125000006308 propyl amino group Chemical group 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 235000020945 retinal Nutrition 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000004334 sorbic acid Substances 0.000 description 3
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 3
- 235000010199 sorbic acid Nutrition 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000008227 sterile water for injection Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- GJJYYMXBCYYXPQ-UHFFFAOYSA-N tert-butyl 2-oxopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1=O GJJYYMXBCYYXPQ-UHFFFAOYSA-N 0.000 description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 3
- IYMAXBFPHPZYIK-BQBZGAKWSA-N (2S)-2-[[2-[[(2S)-2-azaniumyl-5-(diaminomethylideneazaniumyl)pentanoyl]amino]acetyl]amino]butanedioate Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- VLGJWRXCXZTWSC-YRNVUSSQSA-N (E)-1-[6-(difluoromethoxy)pyridin-3-yl]-7-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)hept-1-en-3-one Chemical compound C1=NC(OC(F)F)=CC=C1\C=C\C(=O)CCCCC1=CC=C(CCCN2)C2=N1 VLGJWRXCXZTWSC-YRNVUSSQSA-N 0.000 description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-Propanediol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 2
- 108040005185 1-phosphatidylinositol-3-kinase activity proteins Proteins 0.000 description 2
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 125000001963 4 membered heterocyclic group Chemical group 0.000 description 2
- NRGBKYVUEUMGTE-UHFFFAOYSA-N 6-(difluoromethoxy)pyridine-3-carbaldehyde Chemical compound FC(F)OC1=CC=C(C=O)C=N1 NRGBKYVUEUMGTE-UHFFFAOYSA-N 0.000 description 2
- 101710027066 ALB Proteins 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 229960001950 Benzethonium Chloride Drugs 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M Benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- 108010005144 Bevacizumab Proteins 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N Bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butanoic acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 102100014691 CXCL12 Human genes 0.000 description 2
- 101710043128 CXCL12 Proteins 0.000 description 2
- 102000000905 Cadherins Human genes 0.000 description 2
- 108050007957 Cadherins Proteins 0.000 description 2
- 229960001927 Cetylpyridinium Chloride Drugs 0.000 description 2
- YMKDRGPMQRFJGP-UHFFFAOYSA-M Cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- GUVUOGQBMYCBQP-UHFFFAOYSA-N DMPU Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N Diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- 101700045840 ECT Proteins 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N Ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 230000036499 Half live Effects 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 2
- 210000004072 Lung Anatomy 0.000 description 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 2
- 230000036650 Metabolic stability Effects 0.000 description 2
- 206010027476 Metastasis Diseases 0.000 description 2
- 229950010895 Midostaurin Drugs 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 229940100655 Ophthalmic Gel Drugs 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 101710018346 PDGFRB Proteins 0.000 description 2
- 102100004939 PDGFRB Human genes 0.000 description 2
- 229940099511 POLYSORBATE 65 Drugs 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N Phenethyl alcohol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 2
- 229940099429 Polyoxyl 40 Stearate Drugs 0.000 description 2
- 229920001219 Polysorbate 40 Polymers 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 229920002642 Polysorbate 65 Polymers 0.000 description 2
- 229940068968 Polysorbate 80 Drugs 0.000 description 2
- 229940069338 Potassium Sorbate Drugs 0.000 description 2
- CHHHXKFHOYLYRE-STWYSWDKSA-M Potassium sorbate Chemical compound [K+].C\C=C\C=C\C([O-])=O CHHHXKFHOYLYRE-STWYSWDKSA-M 0.000 description 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 2
- 210000001210 Retinal Vessels Anatomy 0.000 description 2
- 229960003885 Sodium Benzoate Drugs 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M Sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004147 Sorbitan trioleate Substances 0.000 description 2
- 229960000391 Sorbitan trioleate Drugs 0.000 description 2
- IJCWFDPJFXGQBN-BIFNRIDTSA-N Sorbitan tristearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@@H](O)[C@@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-BIFNRIDTSA-N 0.000 description 2
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 2
- 108010006830 TIE receptors Proteins 0.000 description 2
- 102000005450 TIE receptors Human genes 0.000 description 2
- 229920002807 Thiomer Polymers 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L Thiomersal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- MDYZKJNTKZIUSK-UHFFFAOYSA-N Tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 2
- 108091007928 VEGF receptors Proteins 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 208000001756 Virus Disease Diseases 0.000 description 2
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 2
- IYFATESGLOUGBX-NDUCAMMLSA-N [2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-NDUCAMMLSA-N 0.000 description 2
- PRXRUNOAOLTIEF-XDTJCZEISA-N [2-[(2R,3S,4R)-4-hydroxy-3-[(Z)-octadec-9-enoyl]oxyoxolan-2-yl]-2-[(Z)-octadec-9-enoyl]oxyethyl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@@H](O)[C@@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-XDTJCZEISA-N 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 229960002833 aflibercept Drugs 0.000 description 2
- 108010081667 aflibercept Proteins 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 229940121369 angiogenesis inhibitors Drugs 0.000 description 2
- 201000001320 atherosclerosis Diseases 0.000 description 2
- 229960001716 benzalkonium Drugs 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 2
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 108010045325 cyclic arginine-glycine-aspartic acid peptide Proteins 0.000 description 2
- 230000003247 decreasing Effects 0.000 description 2
- 230000002939 deleterious Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L disodium;2-[2-[carboxylatomethyl(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 229940009662 edetate Drugs 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 230000007159 enucleation Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 238000003682 fluorination reaction Methods 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003834 intracellular Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000001810 isothiocyanato group Chemical group *N=C=S 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 2
- CETVQRFGPOGIQJ-UHFFFAOYSA-N lithium;hexane Chemical compound [Li+].CCCCC[CH2-] CETVQRFGPOGIQJ-UHFFFAOYSA-N 0.000 description 2
- 239000002609 media Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229910052751 metal Chemical class 0.000 description 2
- 239000002184 metal Chemical class 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N n-methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
- 239000002114 nanocomposite Substances 0.000 description 2
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 2
- 210000000056 organs Anatomy 0.000 description 2
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229960000639 pazopanib Drugs 0.000 description 2
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000036231 pharmacokinetics Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001993 poloxamer 188 Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 2
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 2
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 2
- 229940101027 polysorbate 40 Drugs 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 239000004302 potassium sorbate Substances 0.000 description 2
- 235000010241 potassium sorbate Nutrition 0.000 description 2
- 230000036515 potency Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 200000000008 restenosis Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- MRTAVLDNYYEJHK-UHFFFAOYSA-M sodium;2-chloro-2,2-difluoroacetate Chemical compound [Na+].[O-]C(=O)C(F)(F)Cl MRTAVLDNYYEJHK-UHFFFAOYSA-M 0.000 description 2
- 229940035044 sorbitan monolaurate Drugs 0.000 description 2
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 2
- 239000001570 sorbitan monopalmitate Substances 0.000 description 2
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 2
- 235000019337 sorbitan trioleate Nutrition 0.000 description 2
- 235000011078 sorbitan tristearate Nutrition 0.000 description 2
- 239000001589 sorbitan tristearate Substances 0.000 description 2
- 229960004129 sorbitan tristearate Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000002459 sustained Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- SHGKWBFIVQKGBS-UHFFFAOYSA-N tert-butyl N-(5-dimethoxyphosphoryl-4-oxopentyl)carbamate Chemical compound COP(=O)(OC)CC(=O)CCCNC(=O)OC(C)(C)C SHGKWBFIVQKGBS-UHFFFAOYSA-N 0.000 description 2
- 239000011778 trisodium citrate Substances 0.000 description 2
- 229960004224 tyloxapol Drugs 0.000 description 2
- 229920001664 tyloxapol Polymers 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 230000003442 weekly Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- PUSNGFYSTWMJSK-GSZQVNRLSA-N (2R,3R,4S,5R,6R)-2,3,4-trimethoxy-6-(methoxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane;1-[[(2R,3R,4S,5R,6S)-3,4,5-tris(2-hydroxypropoxy)-6-[(2R,3R,4S,5R,6R)-4,5,6-tris(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)oxan- Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](OC)O[C@@H]1COC.CC(O)CO[C@@H]1[C@@H](OCC(C)O)[C@H](OCC(C)O)[C@@H](COCC(O)C)O[C@H]1O[C@H]1[C@H](OCC(C)O)[C@@H](OCC(C)O)[C@H](OCC(C)O)O[C@@H]1COCC(C)O PUSNGFYSTWMJSK-GSZQVNRLSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- NDQXKKFRNOPRDW-UHFFFAOYSA-N 1,1,1-triethoxyethane Chemical compound CCOC(C)(OCC)OCC NDQXKKFRNOPRDW-UHFFFAOYSA-N 0.000 description 1
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-Ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-M 1-carboxynaphthalen-2-olate Chemical compound C1=CC=CC2=C(C([O-])=O)C(O)=CC=C21 UPHOPMSGKZNELG-UHFFFAOYSA-M 0.000 description 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
- OGFKTAMJLKHRAZ-UHFFFAOYSA-N 2,2-dimethoxyacetaldehyde Chemical compound COC(OC)C=O OGFKTAMJLKHRAZ-UHFFFAOYSA-N 0.000 description 1
- BQDJLAWUTBCDHK-UHFFFAOYSA-N 2-(trifluoromethyl)pyrimidine Chemical compound FC(F)(F)C1=NC=CC=N1 BQDJLAWUTBCDHK-UHFFFAOYSA-N 0.000 description 1
- KHMGMVNRBZRJLT-UHFFFAOYSA-N 2-chloro-6,7-difluoroquinoline-3-carbaldehyde Chemical compound O=CC1=C(Cl)N=C2C=C(F)C(F)=CC2=C1 KHMGMVNRBZRJLT-UHFFFAOYSA-N 0.000 description 1
- DUIOKRXOKLLURE-UHFFFAOYSA-N 2-octylphenol Chemical class CCCCCCCCC1=CC=CC=C1O DUIOKRXOKLLURE-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-M 3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoate Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GHOKWGTUZJEAQD-ZETCQYMHSA-M 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 1
- TUKUVGKMNSUOJF-UHFFFAOYSA-N 5-bromo-2-(difluoromethoxy)pyridine Chemical compound FC(F)OC1=CC=C(Br)C=N1 TUKUVGKMNSUOJF-UHFFFAOYSA-N 0.000 description 1
- IDDIQDVSYHYORP-UHFFFAOYSA-N 6,7-difluoroquinoline Chemical compound C1=CN=C2C=C(F)C(F)=CC2=C1 IDDIQDVSYHYORP-UHFFFAOYSA-N 0.000 description 1
- WULLFRHOBVUHFT-UHFFFAOYSA-N 6,7-difluoroquinoline-2-carbaldehyde Chemical compound C1=C(C=O)N=C2C=C(F)C(F)=CC2=C1 WULLFRHOBVUHFT-UHFFFAOYSA-N 0.000 description 1
- AEJUXMIUYWGAAZ-UHFFFAOYSA-N 6,7-difluoroquinoline-3-carbaldehyde Chemical compound O=CC1=CN=C2C=C(F)C(F)=CC2=C1 AEJUXMIUYWGAAZ-UHFFFAOYSA-N 0.000 description 1
- PUMHTKUNRZZGSF-UHFFFAOYSA-N 6-fluoroquinoline-3-carbaldehyde Chemical compound N1=CC(C=O)=CC2=CC(F)=CC=C21 PUMHTKUNRZZGSF-UHFFFAOYSA-N 0.000 description 1
- VAQXYTXEFDFLIS-UHFFFAOYSA-M 7,7-dimethyloctanoyloxy(phenyl)mercury Chemical compound CC(C)(C)CCCCCC(=O)O[Hg]C1=CC=CC=C1 VAQXYTXEFDFLIS-UHFFFAOYSA-M 0.000 description 1
- LTXUCTPWYXMADF-UHFFFAOYSA-N 7-(trifluoromethyl)quinoline-2-carbaldehyde Chemical compound C1=CC(C=O)=NC2=CC(C(F)(F)F)=CC=C21 LTXUCTPWYXMADF-UHFFFAOYSA-N 0.000 description 1
- BHIFVHUXECOOJF-UHFFFAOYSA-N 7-(trifluoromethyl)quinoline-3-carbaldehyde Chemical compound C1=C(C=O)C=NC2=CC(C(F)(F)F)=CC=C21 BHIFVHUXECOOJF-UHFFFAOYSA-N 0.000 description 1
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2S)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N AI2O3 Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229940064004 Antiseptic throat preparations Drugs 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 108060001001 BRK1 Proteins 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N Benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 210000004155 Blood-Retinal Barrier Anatomy 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N Bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 210000001775 Bruch Membrane Anatomy 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- 102100003147 CCDC85B Human genes 0.000 description 1
- 101710009963 CCDC85B Proteins 0.000 description 1
- 102100014035 CXCR1 Human genes 0.000 description 1
- 101700011366 CXCR1 Proteins 0.000 description 1
- 241000220450 Cajanus cajan Species 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N Camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 210000001736 Capillaries Anatomy 0.000 description 1
- 229960001631 Carbomer Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229940089960 Chloroacetate Drugs 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N Chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 229960004926 Chlorobutanol Drugs 0.000 description 1
- 229940107161 Cholesterol Drugs 0.000 description 1
- 210000003161 Choroid Anatomy 0.000 description 1
- 229940090805 Clavulanate Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N Clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 241000723368 Conium Species 0.000 description 1
- 210000004087 Cornea Anatomy 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 229940097362 Cyclodextrins Drugs 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- VONWDASPFIQPDY-UHFFFAOYSA-N Dimethyl methylphosphonate Chemical compound COP(C)(=O)OC VONWDASPFIQPDY-UHFFFAOYSA-N 0.000 description 1
- 241000668709 Dipterocarpus costatus Species 0.000 description 1
- CXWGKAYMVASWDQ-UHFFFAOYSA-N Dithiane Chemical compound C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 description 1
- 229960004679 Doxorubicin Drugs 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 102000008745 EC 6.1.1.- Human genes 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- 229950005627 Embonate Drugs 0.000 description 1
- 229950000206 Estolate Drugs 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N Ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 210000002744 Extracellular Matrix Anatomy 0.000 description 1
- 210000000744 Eyelids Anatomy 0.000 description 1
- CIILIXKSSOJGPB-UHFFFAOYSA-N FC(C)(CC1=NC=2NCCCC=2C=C1)F Chemical compound FC(C)(CC1=NC=2NCCCC=2C=C1)F CIILIXKSSOJGPB-UHFFFAOYSA-N 0.000 description 1
- 108091008101 FGF receptors Proteins 0.000 description 1
- 102000027757 FGF receptors Human genes 0.000 description 1
- 240000003139 Ferula foetida Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 229960001731 GLUCEPTATE Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229940065521 Glucocorticoid inhalants for obstructive airway disease Drugs 0.000 description 1
- 206010018987 Haemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 241000229754 Iva xanthiifolia Species 0.000 description 1
- 102100011311 KNG1 Human genes 0.000 description 1
- 229960004184 Ketamine Hydrochloride Drugs 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 229940001447 Lactate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N Lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 101700008982 MMP18 Proteins 0.000 description 1
- 108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N Methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N Methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 description 1
- 206010062198 Microangiopathy Diseases 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-β-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N N-benzyl-1-phenylmethanamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- 229910019093 NaOCl Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- QEFAQIPZVLVERP-UHFFFAOYSA-N Nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 description 1
- GZVMDAXHLBPWBN-UHFFFAOYSA-L O=C(CP([O-])([O-])=O)CCCCC1=NC=2NCCCC=2C=C1 Chemical compound O=C(CP([O-])([O-])=O)CCCCC1=NC=2NCCCC=2C=C1 GZVMDAXHLBPWBN-UHFFFAOYSA-L 0.000 description 1
- 229940049964 Oleate Drugs 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 210000002997 Osteoclasts Anatomy 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 1
- 101710021184 PAPOLB Proteins 0.000 description 1
- 108091007929 PDGF receptors Proteins 0.000 description 1
- 102100012897 PGF Human genes 0.000 description 1
- 101710014083 PGF Proteins 0.000 description 1
- 102100001937 PTPRB Human genes 0.000 description 1
- 101700082725 PTPRB Proteins 0.000 description 1
- 229960001592 Paclitaxel Drugs 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 229960003531 Phenolsulfonphthalein Drugs 0.000 description 1
- XEBWQGVWTUSTLN-UHFFFAOYSA-M Phenylmercury acetate Chemical compound CC(=O)O[Hg]C1=CC=CC=C1 XEBWQGVWTUSTLN-UHFFFAOYSA-M 0.000 description 1
- 229960000502 Poloxamer Drugs 0.000 description 1
- 229950005134 Polycarbophil Drugs 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 229940068918 Polyethylene Glycol 400 Drugs 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N Potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N Propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proxymetacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 1
- 239000007759 RPMI Media 1640 Substances 0.000 description 1
- 206010055666 Retinal neovascularisation Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N Sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N Sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N Sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- JXKPEJDQGNYQSM-UHFFFAOYSA-M Sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
- 229960003212 Sodium propionate Drugs 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 1
- 229950001248 Squalamine Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N Sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 241000212255 Sylvilagus aquaticus Species 0.000 description 1
- 229940037128 Systemic Glucocorticoids Drugs 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 229950002757 Teoclate Drugs 0.000 description 1
- NQSIKKSFBQCBSI-UHFFFAOYSA-N Tetrapropylammonium perruthenate Chemical compound [O-][Ru](=O)(=O)=O.CCC[N+](CCC)(CCC)CCC NQSIKKSFBQCBSI-UHFFFAOYSA-N 0.000 description 1
- 229940033663 Thimerosal Drugs 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N Triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N Triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- 229960005066 Trisodium edetate Drugs 0.000 description 1
- 108020004484 Trp Transfer RNA Proteins 0.000 description 1
- 102100019017 VWF Human genes 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 229960003048 Vinblastine Drugs 0.000 description 1
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229960004528 Vincristine Drugs 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N Xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 Xylazine Drugs 0.000 description 1
- GUBXYMKIJFOYOA-YMGPVYFXSA-N [(2R)-2-formyloxy-3-[hydroxy-[(2R,3S,5R,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropyl] formate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(=O)OC[C@@H](COC=O)OC=O)[C@H](O)[C@@H]1O GUBXYMKIJFOYOA-YMGPVYFXSA-N 0.000 description 1
- OISFUZRUIGGTSD-LJTMIZJLSA-O [NH4+].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO Chemical compound [NH4+].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO OISFUZRUIGGTSD-LJTMIZJLSA-O 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 108010076089 accutase Proteins 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N acetic acid;palladium Chemical compound [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000002945 adventitial reticular cell Anatomy 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic Effects 0.000 description 1
- 230000002491 angiogenic Effects 0.000 description 1
- 230000000964 angiostatic Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000002421 anti-septic Effects 0.000 description 1
- 108090001123 antibodies Proteins 0.000 description 1
- 102000004965 antibodies Human genes 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzyl-dodecyl-dimethylazanium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
- 230000035587 bioadhesion Effects 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000000740 bleeding Effects 0.000 description 1
- 231100000319 bleeding Toxicity 0.000 description 1
- 201000004569 blindness Diseases 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000004378 blood-retinal barrier Effects 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 230000003139 buffering Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 201000005667 central retinal vein occlusion Diseases 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-M chloroacetate Chemical compound [O-]C(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-M 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000004064 cosurfactant Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000005712 crystallization Effects 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N diguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002612 dispersion media Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 125000002587 enol group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-L galactarate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C([O-])=O DSLZVSRJTYRBFB-DUHBMQHGSA-L 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- PZKFYTOLVRCMOA-UHFFFAOYSA-N hept-1-en-3-ol Chemical compound CCCCC(O)C=C PZKFYTOLVRCMOA-UHFFFAOYSA-N 0.000 description 1
- 125000005842 heteroatoms Chemical group 0.000 description 1
- KUQWZSZYIQGTHT-UHFFFAOYSA-N hexa-1,5-diene-3,4-diol Chemical compound C=CC(O)C(O)C=C KUQWZSZYIQGTHT-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000009540 indirect ophthalmoscopy Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive Effects 0.000 description 1
- 238000009114 investigational therapy Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 230000002427 irreversible Effects 0.000 description 1
- 230000003522 irritant Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- VCMGMSHEPQENPE-UHFFFAOYSA-N ketamine hydrochloride Chemical compound [Cl-].C=1C=CC=C(Cl)C=1C1([NH2+]C)CCCCC1=O VCMGMSHEPQENPE-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M laurate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- OCZDCIYGECBNKL-UHFFFAOYSA-N lithium;alumanuide Chemical compound [Li+].[AlH4-] OCZDCIYGECBNKL-UHFFFAOYSA-N 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- XXGJRAFLOAKNCC-UHFFFAOYSA-N methane;molecular hydrogen Chemical compound C.[H][H] XXGJRAFLOAKNCC-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000003641 microbiacidal Effects 0.000 description 1
- 239000002855 microbicide agent Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 108010045030 monoclonal antibodies Proteins 0.000 description 1
- 229960000060 monoclonal antibodies Drugs 0.000 description 1
- 102000005614 monoclonal antibodies Human genes 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000003232 mucoadhesive Effects 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 229960001002 nepafenac Drugs 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N nitrooxy(phenyl)mercury Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 150000002842 nonanoic acids Chemical class 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 230000002148 osteoclast Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M palmitate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960003407 pegaptanib Drugs 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 210000003668 pericytes Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 108091008017 photoreceptors Proteins 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000002062 proliferating Effects 0.000 description 1
- 229960003981 proparacaine Drugs 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000003806 protein tyrosine phosphatase inhibitor Substances 0.000 description 1
- 230000002797 proteolythic Effects 0.000 description 1
- FREJAOSUHFGDBW-UHFFFAOYSA-N pyrimidine-5-carbaldehyde Chemical compound O=CC1=CN=CN=C1 FREJAOSUHFGDBW-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000004263 retinal angiogenesis Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Substances [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- ONXOJZKNAIVOIS-UHFFFAOYSA-M sodium;2-butyl-4-hydroxybenzoate Chemical compound [Na+].CCCCC1=CC(O)=CC=C1C([O-])=O ONXOJZKNAIVOIS-UHFFFAOYSA-M 0.000 description 1
- QYNMSPKSYXPZHG-UHFFFAOYSA-M sodium;4-ethoxycarbonylphenolate Chemical compound [Na+].CCOC(=O)C1=CC=C([O-])C=C1 QYNMSPKSYXPZHG-UHFFFAOYSA-M 0.000 description 1
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical compound [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 description 1
- 230000003381 solubilizing Effects 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- 230000000707 stereoselective Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 229930003347 taxol Natural products 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-M valerate Chemical compound CCCCC([O-])=O NQPDZGIKBAWPEJ-UHFFFAOYSA-M 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 229960001134 von Willebrand factor Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof. (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.
Description
FLUORINATED INTEGRIN ANTAGONISTS
CROSS-REFERENCE TO RELATEDAPPLICATIONS
This application claims priority to and the benefit of U.S.S.N. 61/762,087, filed on
February 7, 2013, and N. 61/900,706, filed on November 6, 2013, the ts of each
of which are incorporated herein by reference in their entireties.
BACKGROUND OF THE INVENTION
Age-related macular degeneration (AMD) is the leading cause of ess in people
over the age of 55; and diabetic retinopathy (DR) is the leading cause in people under 55
(Klein, 1994; Williams, 2004). Both diseases are characterized by new blood vessel growth –
choriodal neovascularization in AMD and retinal neovascularization in DR (Freund, 1993;
Speicher, 2003; Zarbin, 2004). Macular edema occurs when fluid and protein deposits t
on or under the macula of the eye (a yellow central area of the retina) and cause it to thicken
and swell ). Diabetic macular edema (DME) is similarly caused by leaking macular
capillaries. DME is the most common cause of visual loss in both proliferative and liferative
DR. Thrombosis of central retinal vein (CRV) and its branches is the second
most prevalent vascular pathology after DR, and results in abrupt decrease in visual acuity
and is accompanied by macular edema. Thus, anti-angiogenesis treatments are useful in
combating all these conditions.
αv integrins have been shown to be ed in ocular angiogenesis. sion of
αv integrins is upregulated in various diseases or ions, such as AMD and DR, and in
mouse model of oxygen-induced pathy (OIR) or retinopathy of prematurity (ROP)
model (Takagi, 2002). Also, αvβ3 is expressed in new vessels after photocoagulation, but not
in normal choroidal vessels, in the laser-induced choroidal neovascularization model for
AMD (Kamizuru, 2001). Administration of αv integrins antagonists, such as a cyclic RGD
peptide, has been shown to inhibit retinal and choroidal neovascularization (Friedlander,
1996; Chavakis, 2002; Luna, 1996; Riecke, 2001; Yasukawa, 2004).
Angiogenesis inhibitors ing vascular endothelial growth factor (VEGF), other
growth factors (e.g., fibroblast growth factor (FGF), platelet-derived growth factor (PDGF)),
chemokines (e.g., IL8, SDF1, G-CSF), ors (e.g., CXCR1, FGF- R, PlGFR, PDGFR,
Tie-receptors), intracellular mediators (e.g., c-kit kinase, PI3 kinase, PKC), and extracellular
mediators (e. g., integrins, cadherins), as well as inhibitors of pro-angiogenic targets (e. g.,
phosphoinositide 3 kinase), have been investigated for the treatment ofAMD and DR.
However, application of these drugs is limited due to various concerns, such as toxicity and
complexity of administration. Further, av integrins inhibitors tested or currently in clinical
trials for treating AMD and DR are not being successfully developed due to poor ocular
pharmacokinetics and/or high levels of excipient/carrier (e. g., benzalconium chloride and
mannitol) known to cause damage to the eye.
Thus, there continues to be a need for improved compounds, compositions, and
methods for treating AMD, DR, DME, and r edema following retinal vein ion,
that are safe, effective, and conveniently administered. The present invention addresses the
need.
Y OF THE INVENTION
The present invention provides novel fluorinated compounds which are av integrin
antagonists, having formula I:
R R'
/ (I),
or a pharmaceutically acceptable salt or solvate thereof.
The present invention provides a ceutical composition comprising a nd
of the invention or a pharmaceutically acceptable salt or e thereof, and a
pharmaceutically acceptable carrier or excipient.
The present invention also provides a pharmaceutical composition comprising a
compound of the invention or a pharmaceutically acceptable salt or solvate thereof, and a
pharmaceutically acceptable r or excipient, and further an active ingredient selected
from the group consisting of a) an antagonist of integrin @581, b) a xic/antiproliferative
agent, c) an inhibitor of mal-derived, ast-derived, or platelet-derived growth
factor, d) an inhibitor of VEGF, e) an inhibitor of Flk-l/KDR, Flt-l, Tck/Tie-2, or Tic-l, and
f) an inhibitor of phosphoinositide 3-kinase, and a mixture thereof.
The present invention further provides a pharmaceutical ition comprising a
compound of the invention or a pharmaceutically acceptable salt or solvate thereof, and a
ceutically acceptable carrier or excipient, and further an active ingredient selected
from the group consisting of a) an antagonist of integrin @581, b) a xic/antiproliferative
agent, c) an tor of epidermal-derived, fibroblast—derived, or platelet-derived growth
WO 24302
factors, d) an inhibitor of VEGF, and e) an tor of phosphoinositide 3-kinase, and a
mixture thereof.
The present invention provides a method of treating or preventing a disease or
condition in a subject, comprising administering to a subject in need thereof a therapeutically
effective amount of a compound of the invention or a pharmaceutically acceptable salt or
solvate thereof or a therapeutically effective amount of a pharmaceutical composition of the
invention. In one aspect, the invention es treating a disease or ion. In one
, the invention provides preventing a disease or condition. In one aspect, the
compound or pharmaceutical ition ofthe invention is administered topically.
The present ion provides a method of treating or preventing a disease or
condition mediated by an (xv integrin in a subject, sing administering to a subject in
need thereof a therapeutically effective amount of a compound of the invention or a
pharmaceutically acceptable salt or solvate thereof or a therapeutically effective amount of a
pharmaceutical composition of the invention. In one aspect, the disease or condition is a
disease or condition in which angiogenesis is involved. In a further aspect, the disease or
condition is a disease or condition in which ocular enesis is ed.
The present invention also provides a method of treating or preventing an (va3
and/or (va5 integrin-mediated disease or condition in a subject, comprising administering to
a subject in need thereof a eutically effective amount of a compound of the invention or
a pharmaceutically able salt or e f or a therapeutically effective amount of
a pharmaceutical composition of the invention. In one aspect, the disease or condition is a
disease or condition in which ocular angiogenesis is involved. In one aspect, the disease or
condition is macular degeneration. In one , the disease or condition is age-related
macular degeneration (AMD). In one aspect, the e or condition is diabetic retinopathy
(DR). In one aspect, the disease or condition is diabetic macular edema (DME). In one
, the disease or condition is macular edema following retinal vein occlusion (RVO).
The present invention fiirther provides a method of treating or preventing AMD, DR,
DME, or macular edema following RVO, comprising administering to a subject in need
thereof, a therapeutically effective amount of a compound of the invention or a
pharmaceutically acceptable salt or solvate f or a therapeutically effective amount of a
pharmaceutical composition ofthe invention. In one aspect, the invention provides treating
AMD, DR, DME, or macular edema ing RVO. In one aspect, the invention provides
preventing AMD, DR, DME, or macular edema following RVO.
The present invention r provides a method of treating or preventing a e or
condition in a subject, comprising stering to a subject in need thereof a therapeutically
effective amount of a compound of the invention or a pharmaceutically acceptable salt or
solvate thereof or a therapeutically effective amount of a pharmaceutical composition of the
ion, in combination with one or more therapies for treating or preventing the disease or
condition. In one aspect, the disease or condition is mediated by an av integrin. In a further
aspect, the disease or condition is mediated by an avB3 and/or avBS integrin. In one aspect,
the disease or condition is a disease or condition in which enesis is ed. In a
further aspect, the disease or condition is a disease or condition in which ocular angiogenesis
is involved. In one aspect, the therapy is an anti-VEGF therapy. In a further aspect, the anti-
VEGF therapy is intravitreally injected.
The present invention provides the use of a compound of the invention or a
pharmaceutically acceptable salt or e thereof in ng or preventing a disease or
condition in a subject. In one aspect, the use is for treating a disease or condition. In one
aspect, the use is for preventing a disease or condition. In one aspect, the compound or
ceutical composition of the invention is formulated for use in topical stration.
The t ion provides the use of a compound of the invention or a
pharmaceutically able salt or solvate thereof in the manufacture of a medicament for
the treatment or prevention of a disease or condition in a subject. In one aspect, the invention
provides for the treatment of a e or condition. In one aspect, the invention provides for
the prevention of a disease or condition. In one aspect, the medicament is formulated for
topical administration.
Unless otherwise defined, all technical and scientific terms used herein have the same
meaning as commonly understood by one of ordinary skill in the art to which this invention
belongs. In the case of conflict, the present specification, including definitions, will control.
In the specification, the singular forms also include the plural unless the context clearly
dictates otherwise. Although methods and materials similar or equivalent to those described
herein can be used in the practice or testing of the t invention, suitable methods and
materials are described below. All ations, patent applications, patents, and other
nces mentioned herein are incorporated by reference. The references cited herein are
not admitted to be prior art to the claimed invention. In addition, the materials, methods, and
examples are illustrative only and are not intended to be limiting.
Other es and advantages of the invention will be apparent from the following
detailed description and claims.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1. A bar graph showing blood vessel counts (score) in the chick CAM assay,
Figure 2. A bar graph showing plasma and ocular distribution of Compound Al in rabbit «
Figure 3. A bar graph showing plasma and ocular distribution of Compound A2 in rabbit ,
Figure 4. A bar graph showing plasma and ocular distribution of nd A3 in rabbit.
Figure 5. Representative Fluorescein raphy (FA) images of the eye on day 35 in
animals following twice daily topical administration of (A) 50 uL Compound Al, (B) 50 uL
Compound A2, (C) 50 uL vehicle ,
DETAILED DESCRIPTION OF THE INVENTION
It is believed that a wide variety of diseases and conditions can be treated or ted
by inhibiting processes mediated by ow integrins. Thus, ow integrin antagonists represent a
useful class of drugs for treating or preventing those diseases and conditions. ins are
heterodimeric embrane proteins through which cells attach and communicate with
extracellular es and other cells. The ow integrins are key receptors involved in
mediating cell migration and enesis. Antagonists ofthe integrins ocvli3 and ocvliS are
useful for treating and preventing bone resorption, osteoporosis, vascular restenosis, diabetic
retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, viral disease,
tumor , and metastasis.
ow integrins have also been found to be involved in ocular angiogenesis, a process that
can lead to various ocular diseases, such as age-related macular degeneration (AMD), diabetic
retinopathy (DR), diabetic macular edema (DME), and macular edema following retinal vein
occlusion (RVO) d, 1993; Speicher, 2003; Zarbin, 2004). Pro-angiogenic growth
factors, including VEGF and FGF, are up—regulated in AMD and DR, which, in turn,
stimulate ow integrin sion. In the well-established mouse model of -induced
retinopathy (OIR) or retinopathy of prematurity (ROP) model, ow integrins and the ligand
osteopontin are pressed in neovascular endothelial cells during the peak time of retinal
vessel growth (Takagi, 2002). Cyclic peptides mimicking the arginine-glycine-asparagine
(RGD) binding motif, through which ow integrins bind to their extracellular matrix ligands,
have been shown to inhibit retinal neo-vascularization in the mouse OIR model via various
routes of administration (e. g. , subcutaneous, intraperitoneal, periocular, or topical)
(Friedlander, 1996; Chavakis, 2002; Luna, 1996; Riecke, 2001). Also, in the laser-induced
choroidal cularization model (rats), a well-accepted model for AMD, integrins ocvli3
WO 24302
and von Willebrand factor are expressed on elial cells ofnew vessels after
photocoagulation, but not in normal dal s (Kamizuru, 2001). In this model,
intravitreal injection of a cyclic RGD peptide significantly reduces the development of
choroidal cularization (Yasukawa, 2004). In humans, expression of avB3 and avBS,
which are not expressed in normal retinal tissue, is observed in vascular cells in the eyes of
DR patients (Friedlander, 1996; Luna, 1996), and high levels of avBS expression is primarily
observed in ocular tissues in AMD ts (Friedlander, 1996).
Diseases or conditions of the retina (which is located at the back of the eye), including
macular degeneration, DR, DME, and macular edema following RVO, are very difficult to
treat by ic administration (e. g., oral, intravenous, nasally, or inhalation) because
the retina is difficult to access from the systemic circulation due to the blood—retinal r.
Therefore, currently ed treatments (e.g., anti-VEGF proteins or a chemically-modified
anti-VEGF aptamer) for macular degeneration, DME, and macular edema following RVO
must be repeatedly administered by intra-ocular injection (intravitreal administration).
Many angiogenesis inhibitors targeting vascular endothelial growth factor (VEGF)
(e. g. the VEGF aptamer, pegaptanib, and the VEGF or VEGF receptor (VEGFR)-targeted
monoclonal antibodies, bevacizumab, ranibizumab, aflibercept) have been investigated for the
treatment ofAMD and DR. However, only pegatanib, ranibizumab, aflibercept are approved
by the Food and Drug Administration. Further, all the VEGF-targeted drugs must be
administered by itreal injection to treat AMD or DR. Intravitreal injection requires
adequate anesthesia and a spectrum microbicide, and the insertion of a syringe needle
into the eye using aseptic conditions, thus necessitating the administration to be performed in
a physician’s office. For example, the dosage and administration section of the ranibizumab
Package Insert describes the complex requirements for administering the drug in a safe and
effective manner: all of the ranibizumab vial contents are withdrawn h a 5-micron, 19-
the filter
gauge filter needle attached to a 1—cc tuberculin syringe under aseptic technique;
needle should be ded after withdrawal of the vial contents and should be replaced with a
sterile 30-gauge x 1/2-inch needle for the intravitreal injection; the contents should be
expelled until the r tip is aligned with the line that marks 0.05 mL on the syringe; the
intravitreal injection procedure should be carried out under controlled aseptic conditions (e. g.,
using e gloves, a sterile drape, and a sterile eyelid speculum).
In addition to the practical limitations and strictures related to the need for intravitreal
injection in the treatment of ocular es, VEGF-targeted drugs only address VEGF-
promoted angiogenesis, but not angiogenesis promoted by other growth factors, including
fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF). Targeting
angiogenic molecules other than, or in addition to VEGF, may reveal more effective and safer
inhibitors of intraocular neovascularisation. Potential targets e growth factors (e. g.,
angiopoietin, FGF, HGF, lGF-l, PDGF-B, PlGF), chemokines (e. g., 1L8, SDF1, G—CSF),
receptors (e.g., CXCRl, FGF- R, PlGFR, PDGFR, Tie-receptors), intracellular mediators
(e. g., c—kit kinase, PI3 kinase, PKC), and extracellular mediators (e.g., integrins, cadherins).
Several drugs which do not selectively target VEGF have indeed shown anti-angiogenic
efficacy in eyes: Pazopanib (which blocks PDGFRS, 0- Kit, FGFR, and c-fms) suppresses
choroidal neovascularization in mouse models; and PKC412 (which blocks PKC, VEGF-R,
PDGF-R and SCF-R isoforms) reduces r oedema in diabetics (Doukas, 2008;
Takahashi, 2009; Campochiara, 2004). ents that combine the action of the VEGF-
ed therapies with inhibition of one of these other growth factors have also been studied.
For e, a Phase 3 clinical trial is underway testing the combination of ranibizumab and
the anti-PDGF antibody designed E10030 (ClinTrials.gov, NCT0194483 9). However, these
therapies are limited by safety concerns and complexity of administration, such as liver
toxicity observed following oral administration of PKC412, and intravitreal administration of
ranibizumab and E10030.
r approach for treating or ting ocular diseases is to selectively target a
distinct pro—angiogenic target, such as PI3K. A broad-spectrum PI3K inhibitor LY294002
in rodents
sses retinal or choroidal neovascularisation following intraocular injection
(Yang, 2009). Additional alternative treatments for AMD and DR involving intravitreal
administration of l small molecule inhibitors which prevent enesis (e. g.,
fibronectin receptor antagonists, JSM6427 (Clin Trials.gov, NCT00536016) and ATN—l61
(Wang, 2011), vascular endothelial protein tyrosine phosphatase inhibitors (ClinTrials.gov,
NCT01702441), and mTOR inhibitors, sirolimus, and Palomar 529 (Jacot, 2011)) are being
tested in animals or in clinical trials. Further, combination therapies involving multiple foci
of pro-angiogenic pathways with several selective inhibitors (e. g., combining angiostatic
therapy with a VEGF aptamer, an integrin antagonist, and a proteolytic fragment of
tryptophan tRNA synthetase) have been shown to t ocular angiogenesis (Dorrell, 2007).
Despite these studies and clinical trials, no therapy with a favorable y and safety
profile has been ed.
Recent advances in drug ry technology, including formulation, polymer
chemistry, chnology, microdrug devices, and surgical advancements, have offered new
s and opportunities for topical ocular drug administration. These logies include
the use of hydrogels, mucoadhesive polymers, extrins, nanocomposite formulations,
micellar and lipid nanoparticles, niosomes, microemulsion, microspheres, and prodrug
tization. For instance, nanocomposites have been used to deliver Diclofenac (Cao,
2011), and topical administration of Nepafenac has been shown to reduce the extent of
microangiopathy in animal models ofDR (Kern, 2007) and oxygen-induced retinopathy
(Yanni, 2010). Also, nanoparticle technology has been employed to enhance the surface
penetration of hydrophobic compounds such as glucocorticoids to posterior ocular structures
(Diebold, 2010), and injection of nanoparticles into the vitreous has demonstrated intraretinal
localization for l months after initial dosing and therefore can be used as a localized
drug release depot (Bourges, 2003). Topical administration using eye drops (e.g., eye drop
formulation comprising TG100572, which inhibits FGF, PDGF and VEGF (Doukas, 2008),
or tyrosine kinase tors (TKIS) (e. g, sorafenib (WO2013/000909), bradykinin or
antagonists (ClinTrials. gov, NCT013 l 9487), or an anti—microbial agent, squalamine
(ClinTrials. gov, NCT01678963)) has been studied or is under investigation. However, none
of these approaches have been shown to be suitable for replacing the current rd anti—
VEGF treatments that require itreal injection.
Oral or topical stration of drugs that inhibit (xv integrins (e.g., cyclic penta-
e inhibitor of OMB and ochS, RGDfV, cilengetide, and the non-peptide OMB and
ochS antagonist, INJ-26076713 and EMD478761), for e, by means of a polyvinyl
alcohol-based reservoir implant, has been tested or is currently in clinical trials for treating
AMD and DR (Friedlander, 1996; Santulli, 2008; Fu, 2007). Cyclo-RGDfV was also tested
in a mouse model of retinopathy of urity administered by topical administration
e, 2000); however, the compound needed to be administered six times a day, due to the
of the compound that
poor ocular pharmacokinetics of the nd (116., the amount
distributes to the retina after administration as eye drops, and then maintains an adequate
retinal concentration between administrations). In addition, the peptide was formulated with
high levels of conium chloride and mannitol, which are known to cause damage to the
To date, the
eye. As a result, topical administration has not been successfully developed.
most recent approach to treating ocular angiogenesis is through intravitreal injection of ALG-
1001 (a synthetic oligo-peptide inhibitor of (va3, (vaS, and (1581), which cannot be
administered topically.
The present invention relates to novel fluorinated compounds, which are antagonists
of the av integrins, particularly integrins (va3 and/or (vaS. The compounds of the present
invention or pharmaceutically acceptable salts or solvates thereof are useful in treating or
preventing bone resorption, osteoporosis, ar restenosis, atherosclerosis,
inflammation, viral disease, tumor growth, or metastasis. In particular, the compounds of
the present invention or ceutically acceptable salts or solvates thereof and
pharmaceutical composition comprising the compounds are effective in treating macular
degeneration, DR, DME, and macular edema following retinal vein occlusion (RVO) when
administered topically.
Prior ts to use small molecule integrin antagonists by topical administration
have not succeeded because those compounds lack the appropriate physiochemical
ties (e. g., lipophilicity, molecular size and polar surface area) to allow delivery of
therapeutically effective amounts of those compounds by a convenient formulation and
dosing regimen. The compounds of the present ion have been surprisingly shown to
distribute to the retina after topical administration in therapeutically effective amounts to
inhibit the function of integrins avB3 and avBS and thus treat or prevent retinal
angiogenesis. The compounds of the present invention have advantages such as providing
improved potency, selectivity, tissue penetration, half-life, and/or metabolic stability, and
sfill distribution to the retina in therapeutically effective s via ient
topical stration to the eyes.
Compounds of the Invention
The present invention relates to novel fluorinated compounds of formula I:
R R'
/ (I),
or a pharmaceutically acceptable salt or solvate thereof, wherein:
gNJKNA;
\ /
Z is 5W2 or \_J ;
R and R’ are each independently H or F, or R and R”, together with the carbon atom
to which they are ed, form a 3- or ered carbocyclic or heterocyclic ring;
if; no?R1
QiS N
or R3 -
X is CH or N;
Y is CH or N;
R1 is C1-C4 alkyl substituted with 1, 2, 3, 4, 5, 6, 7, 8, or 9 fluorine atoms, or C1-C6
alkoxy substituted with O, 1, 2, 3, 4, 5, 6, or 7 fluorine atoms; and
R2 and R3 are each independently H, F, CH2F, CHF2, or CF3, provided that one of R2
and R3 is not H,
provided that the compound of formula (I) contains at least one fluorine atom.
The compounds of the present invention contain at least one fluorine atom. In one
aspect, the compounds of the present invention contain at least one fluorine atom in the R or
R’ substituent. In another aspect, the compounds of the present invention n at least one
fluorine atom in the R1 substituent. In another aspect, the compounds ofthe present
invention contain at least one fluorine atom in the R2 or R3 substituent. Fluorination at any
particular position, such as that t in the compounds of the ion, has not been
taught or ted.
mks:
In one aspect, Z is Filmy In another , Z is L—J
In one aspect, R and R’ are each H. In another aspect, R and R’ are each F. In
another aspect, R is H and R’ is F.
In another aspect, R and R’, together with the carbon atom to which they are attached,
form a 3- or 4-membered carbocyclic or heterocyclic ring. In a further , R and R’,
together with the carbon atom to which they are attached, form a 4-membered heterocyclic
ring. In a fiirther embodiment, the 4-membered heterocyclic ring is an oxetane ring. For
e, the oxetane ring is an oxetanyl ring or oxetanyl ring.
EffxYA
In one aspect, Q is R1. In one aspect, X is N and Y is CH. In r aspect,
X and Y are each CH. In another aspect, X and Y are each N.
In one aspect, R1 is straight chain C1-C4 or branched C3-C4 alkyl, and is substituted
with 1, 2, 3, 4, 5, 6, 7, 8, or 9 fluorine atoms. In a fiirther aspect, R1 is , ethyl, propyl,
or butyl, and is substituted with 1, 2, 3, 4, 5, 6, 7, 8, or 9 fluorine atoms. In a further aspect,
R1 is methyl substituted with 1, 2, or 3 fluorine atoms. In a further aspect, R1 is CF3.
In another aspect, R1 is straight chain C1-C6 or branched C3-C6 , and is
substituted with 0, 1, 2, 3, 4, 5, 6, or 7 fluorine atoms. In a further aspect, R1 is methoxy,
ethoxy, propoxy, or butoxy, and is substituted with O, 1, 2, 3, 4, 5, 6, or 7 fluorine atoms. In a
fiirther aspect, R1 is y substituted with 0, 1, 2, or 3 fluorine atoms. In a further aspect,
R1 is OCH3, OCH2F, OCHF2, or OCF3. In a further aspect, R1 is OCHF2.
In r aspect, Q is N R3
In one aspect, R2 is F. In a further aspect, R2 is F and R3 is H. In another aspect, R2 is
CH2F, CHF2, 01‘ CF3.
In one aspect, R3 is F. In a further aspect, R3 is F and R2 is H. In another aspect, R3 is
CH2F, CHF2, or CF3. In a r aspect, R3 is CF3. In a further aspect, R3 is CF3 and R2 is H.
In one aspect, R2 and R3 are each F.
In one aspect, Z1s \_/N}{ and Qis ACA
In a further aspect, Z1s 51$ Q.fCAR1; and R and R’ are each H.
In a further aspect, Z1s z.& ,Q1s ACAR1; R and R’ are each H; and R1is
OCH3, OCH2F, OCHF2, or OCF3. In a further aspect, X is N and Yis CH; and R11s OCHF2.
In one aspect, Z is fWi‘Z and Q is
In a further aspect, Z is 5W2} Q1s ACAR1,and X and Y are each N. In a
further aspect, R1 is methyl substituted with 1, 2, or 3 e atoms. In a further aspect, R1
is CF3.
In another further aspect, Z is f\/\}{; Qis ACAR1,and Xis N and Yis CH. In
a further aspect, R1 is OCH3, OCH2F, OCHF2, or OCF3. In a further , R1is OCHF2.
>3(AlR2\
In one aspect, Z is f\/\}{ and Q is N R3
In one aspect, a compound of present invention is of formula II:
N N\ Z/‘\/COOH
1 R R,
/ (11),
or a pharmaceutically acceptable salt or solvate f, wherein each of the variables are
as defined above. Compounds of the present invention include compounds of formula 11,
wherein the variables are rated in the s aspects of formula I above.
Representative compounds of the present invention include the compounds listed in
Table 1.
Table 1
Cmpd # Chemical Structure Cmpd # Chemical Structure
A1 OCHFz A8 OCHF2
o _/ o O ./ o
H E H
N le NJLNVkOH N le NJLNVkOHE
\—/ \_/
/ /
A2 0 A9 OCHF2
H 1 :N
\ / N O O
I :
/ \NkCF H N\ NJLNVkOH
3 l
/ F F \—/
A3 0 A10 We
a I L”
\ / O _ O
l I H NJLNVkOHE N
/ \N N\
OCHF2 l
/ F F \_/
A4 0 A11 iCHFz
H Nl \N
N N\ F
/ 0 K) o
l l H §
/ \N |N\ NfiNVkOH
A5 A12 iCHFZ
A6 0 A13
2:1: N F
/ \
A7 0 A14 OCHFZ
ZI N O E: O
/ \ .
1 l H
/ / N\ NANA/[L0H
N CF3 i/FFL—J
In one aspect, a compound of the present invention is selected from compounds Al,
A2, and A3, or a pharmaceutically acceptable salt or solvate thereof. In a r aspect, a
compound of the present invention is selected from compounds Al and A2, or a
pharmaceutically acceptable salt or solvate thereof. In a further aspect, a compound of the
present invention is compound Al, or a pharmaceutically acceptable salt or solvate thereof.
In one aspect, a compound of the present invention is a pharmaceutically acceptable
salt. In one aspect, a compound of the present ion is a solvate. In a further aspect, a
compound of the present invention is a hydrate.
In one aspect, a nd of the present invention inhibits the activity of av integrins
(e.g., avB3 and avBS) at a submicromolar concentration, e. g., below 1 uM, 0.8 uM, 0.6 uM,
0.5 uM, 0.2 uM, or 0.1 uM.
In one aspect, a compound of the present ion inhibits cellular adhesion to
vitronectin through the OLV integrin (e. g., avB3 and avBS) at or below an ICso of 2.0E—07 M
using a human dermal microvascular endothelial cell (HMVEC) assay. In a further aspect, a
compound of the present invention inhibits cellular adhesion to vitronectin through the ocv
integrin (e. g., avB3 and avBS) at or below an IC50 of 8 M using an HMVEC assay. In
a further aspect, a compound of the present invention inhibits cellular adhesion to vitronectin
through the ocv integrin (e.g., avB3 and avBS) at or below an ICso of 1.0E—08 M using an
HMVEC assay. In one aspect, a compound of the present invention inhibits cellular adhesion
to vitronectin through the ocv in (e. g., avB3 and avBS) at or below an IC50 of 2.5E—07 M
using a rat lung microvascular endothelial cell (RLMVEC) assay. In a further aspect, a
nd of the present invention inhibits cellular adhesion to vitronectin h the ocv
in (e. g., avB3 and avBS) at or below an IC50 of 3.5E-08 M using an RLMVEC assay. In
one aspect, a compound of the t invention inhibits cellular on to ectin
through the ocv integrin (e. g., avB3 and avBS) at or below an IC50 of 2.0E—08 M using a rabbit
aortic elial cell (RAEC) assay. In a further aspect, a compound of the present
invention inhibits cellular adhesion to vitronectin through the ocv integrin (e.g., avB3 and
avBS) at or below an ICso of 1.0E—08 M using an RAEC assay.
In one aspect, a compound of the present ion inhibits or decreases formation of
blood vessels in a tissue or organ, in vivo or in vitro. In one aspect, a compound of the
present invention decreases the ion of blood vessels below 90%, 80%, 70%, 60%,
50%, 40%, 30%, 20%, 10%, or 5%, as compared to that in an untreated control. In a further
aspect, a nd of the present invention decreases the formation of blood vessels below
60%, 50%, 40%, 30%, 20%, 10%, or 5%, as compared to that in an untreated control. In a
r aspect, a compound of the present ion decreases the formation of blood vessels
below 40%, 30%, 20%, 10%, or 5%, as compared to that in an untreated control. In one
aspect, the tissue is a tissue from the eye, such as a retinal tissue. In one aspect, the organ is
the eye.
In one aspect, a compound of the present ion is efficiently buted to the
back of the eye, e.g., retina, after topical administration. In one aspect, a compound of the
present invention is efficiently distributed to the retina within 12 hours, 10 hours, 8 hours, 6
hours, 4 hours, 2 hours, or 1 hour, after topical administration to the eye. In a further aspect,
a compound of the present invention is ntly distributed to the retina within 8 hours, 6
hours, 4 hours, 2 hours, or 1 hour, after topical administration to the eye.
Compounds of the present invention can be conveniently prepared by a variety of
methods familiar to those skilled in the art. The compounds of each of the formulae described
herein may be prepared according to the following procedures from commercially available
starting materials or starting materials which can be prepared using ture procedures.
These procedures show the preparation of representative compounds of this ion. It is
understood that compounds of the present invention other than those illustrated in the
following schemes can be made using these schemes with modifications ly known in
the art (e. g., using different ng material, changing reaction solvents, or adjusting reaction
duration or temperature).
Scheme 1
OCHFZ
OCHFZ OCHF2
OCHFZ
O N \
OCHFZ fCOZtBu
N \ N \ Pd/C—Hz I
Pd(0AC)z. TEA l J: (Meobcmm /
NH OZNa '
N \ Ph NHBn / 4095i 'r
/ “f \ 0
I -'————’
——————> ————> ——————>
‘ _
_ /
/ Step-l / (o-tolyl)3P nBuLl E
‘ Step~4 0 Step-5 N/\/U\O(:
Step-2 /\/CO B I
/ Step-3 BnN
Br Br X HZN/K/lL0'3” J:
co ‘B HCO OCH3 u 3
1 2 32 Ph $029
0an2 OCHF2 OCHFZ
N \ N \ N \
1/ I/ ah l/
NaCNBH3 O (CI3CO)2CO O O 0
: EI3N 0
z H2504
HN/\/U\O‘BUI C1)J\N/\/U\O‘BuI ‘—F
S‘ep'fi 532:7 Step-8 N\ 5‘°P'9
| fi’U‘NNJLo‘Bu:
kj/OMe OMe /, OMe
OMe OMe OMe
8 9
ocmr2 ocx-IF2
N \ N \
I ‘
/ /
o o O O H
H j:
lLO‘Bu —’2 Pd/C-HZ H i TFA N N\ N
N N\ N N\ NJLNK/lLO‘Bu
I 777’ |
__ mpm 3/ H22
ll 12 Step-ll A]
DIPA
O=(j—-—-——>(B0020 __—,Hexyllithium M20 9
DMAP 1'3 dimethylmethyl MeO’
S‘BP- 1 phosphonate
Ia Step-2
CH0 NaOH
__———>
water, MeOH
Step-3 6b
Scheme 2
H 9
N N\ P—OMe
I OMe
/ tBuOK
________—__>
OHC\
H N / LiAlH4
\ Q ———-—-—-——'—>
I THF
1. EtCOzH
MeC((OEt)3 HO
H N
TFA, MeOH
1‘ Q
3. NaOH, H20 /
MeOH
/N NH2
acetone N N NCS
l N N
proline \ \ AIBN \ \ CI
\ H —-» 1 —-» l
EtOH / / CCI4 / /
A B C BuLi
+ ———>
DMPU
1. propane-1,3—diol
EtO S
0E1 S
2. BOCZO, Et3N
D E
N N N N
\ \ NHBoc Fluorlnatlon. _ \ \ NHBoc
I S S -——> I
/ / V F F
1. H2,Pt02
2. Acid
: n E
i \
I NH2§
i F F
/ i
H E
Scheme4
NHB°C M60
MeO 2. 1,2-ethanedithiol
P O \ nBuLi
n=0,1
N N
o (kw o A, NaOH \ \ NHBoc Fluorlna’uon.
i S S ---—>
Me0/,P”M *9NHBOC / /
H20, EtOH
MeO LM)
R F n=0,1
N\ N\ 1 H2,Pt02 3 H N
NHBOC
I 2 \ NHZ;
F F
/ / 2 ACId g I F F :
Schemes
O O OH O O
‘d l DMAP
/N| N\ 1 ‘ Th‘Iocar onyb Id"um: azoe, N N
H EtOJVBr /Nl N\ OEt / \ OEt
_________________________________ , I F
\ / ......._F__’_:____, \ / F
\ / F F 2.BU3SnH,AIBN
8 T U
EWH"""""""""""""""E
1_ LiBH4 /N N\ P102, H2 1 N
N3 N\ NH2 E
2- szQPYr I """"""""" ’
F F : |
\ / / F F 5
.............. .> .
3 NaN3 ; H
Scheme6
. Me
\/0 1‘ ”202 Me
['11 MeMgBr N02 N\ NH2
N02 --------- * MeO No2 --—--—-----»
o + [
o 2. (00002; o / H
MeONHMe O
J K L
.-:°.'.n.e.- /N [w ___“_2:_'°_‘_‘32_, s \
I s
EtOH \ / /
O E O i
Scheme 7
o 0 B00
NH N Me
30620 MeMgBr NHBoc |N\ NH2
——————————— -> -——-—-> O +
O / H
O O o
ro ne /N N\ 1' H2,Pt02 ; g
. '
_____1---, NHBoc NH2
I ------------- > : | :
EtOH \ / /
o 2‘ Acid E O ;
Scheme 8
N NH2
HOWNHz 1 Soc 0 H 1' MeMgBr Me \
NHBoc l
--------- -> WNHBOC --————------> + / H
o 2. Swern Ox. 0
o 2 TPAP 0
T U R
Pro meI n
/N N‘ N
------ * ””300
l ..1__.H.2_-Pt0.2, NHz
EtOH \ / /
o 2. Acid 0
The compounds of the invention may contain one or more asymmetric s and can
thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures
and individual reomers. Additional asymmetric centers may be present depending upon
the nature of the various substituents on the molecule. Each such asymmetric center will
independently produce two optical isomers. It is intended that all of the possible optical
isomers and diastereomers in mixtures and as pure or partially purified compounds are
included within the ambit of the invention. The invention is meant to comprehend all such
isomeric forms of these compounds.
The independent syntheses of these diastereomers or their chromatographic
separations may be achieved as known in the art by appropriate ation of the
methodology disclosed . Their absolute stereochemistry may be determined by the x—
ray crystallography of crystalline products or lline intermediates which are tized,
if necessary, with a reagent containing an asymmetric center of known absolute
configuration.
If desired, racemic mixtures of the compounds may be separated so that the individual
omers are isolated. The separation can be carried out by methods well known in the
art, such as contacting a racemic mixture of compounds with an enantiomerically pure
compound to form a diastereomeric mixture, followed by separation of the individual
diastereomers by rd methods, such as onal crystallization or chromatography.
The diasteriomeric mixture is often a mixture of diasteriomeric salts formed by contacting a
c mixture of compounds with an enantiomerically pure acid or base. The
diasteromeric derivatives may then be ted to the pure enantiomers by cleavage of the
added chiral residue. The racemic mixture of the compounds can also be separated directly
by chromatographic methods utilizing chiral stationary phases, which are well known in the
art.
Alternatively, any enantiomer of a compound may be obtained by stereoselective
synthesis using optically pure starting materials or reagents of known configuration by
methods well known in the art.
Some of the compounds of the invention may exist in unsolvated as well as solvated
forms such as, for example, hydrates.
“Solvate” means a solvent addition form that contains either a stoichiometric or non-
stoichiometric amounts of the solvent molecules. Some compounds have a tendency to trap a
fixed molar ratio of the solvent molecules in the crystalline solid state, thus forming a solvate.
If the solvent is water, the e formed is a hydrate. When the solvent is l, the
solvate formed is an alcoholate. Hydrates are formed by the ation of one or more
molecules of water with one of the substances (e. g. , a compound of the invention) in which
the water retains its molecular state as H20, such ation being able to form one or more
hydrate. In hydrates, the water molecules are attached through secondary ies by
intermolecular forces, in particular hydrogen bridges. Solid hydrates contain water as so-
called crystal water in stoichiometric ratios, where the water molecules do not have to be
lent with respect to their g state. Examples of hydrates include sesquihydrates,
monohydrates, dehydrates, and trihydrates. y le are the hydrates of salts of the
compounds of the invention.
For use in medicine, the salts of the compounds of the invention refer to xic
“pharmaceutically able salts”. Other salts may, however, be useful in the preparation
of the compounds of the invention or pharmaceutically acceptable salts f. Salts
encompassed within the term “pharmaceutically acceptable salts” refer to non-toxic salts of
the compounds of the invention which can be prepared by reacting the free base with a
suitable organic or inorganic acid. Representativesalts include the ing: acetate,
benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, camsylate,
carbonate, chloride, clavulanate, citrate, dihydrochloride, e, edisylate, estolate, e,
fumarate, gluceptate, ate, glutamate, glycollylarsanilate, hexylresorcinate,
hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate,
lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate,
methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, oleate,
e, pamottle (embonate), palmitate, pantothenate, phosphate/diphosphate,
polygalacturonate, salicylate, stearate, sulfate, subacetate, succinate, tannate, tartrate, teoclate,
tosylate, triethiodide, and valerate. rmore, where the compounds of the invention carry
an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal
salts, e. g., sodium or potassium salts; alkaline earth metal salts, e. g., calcium or magnesium
salts; and salts formed with suitable organic ligands, e. g., quaternary ammonium salts which
may be d from ammonia or organic , such as, for example, diethylamine,
triethylamine, ethyldiisopropylamine, procaine, dibenzylamine, N-methylmorpholine,
oabietylamine, or methylpiperidine.
The invention includes within its scope prodrugs of the compounds of the invention.
In general, such prodrugs will be onal derivatives of the nds of the invention
which are readily convertible in vivo into the required compound. Thus, in the methods of
treatment of the invention, the term “administering” shall encompass the treatment of the
various disease and conditions described with the compound specifically disclosed or with a
compound which may not be specifically disclosed, but which converts to the specified
compound in vivo after stration to the patient. Conventional procedures for the
selection and preparation of suitable prodrug derivatives are described, for e, in
“Design of Prodrugs,” ed. H. Bundgaard, Elsevier, 1985. Metabolites of these compounds
include active species produced upon introduction of compounds of the invention into the
biological milieu.
The invention also includes one or more metabolites of a compound of the invention.
The present invention also comprehends ium labeled compounds of a I
or II or the compounds listed in Table 1, wherein a hydrogen atom is replaced by a deuterium
atom. The deuterium labeled compounds comprise a deuterium atom having an abundance of
deuterium that is substantially greater than the natural abundance of deuterium, e.g., 0.015%.
The term “deuterium enrichment factor” as used herein means the ratio between the
deuterium nce and the natural abundance of a deuterium. In one aspect, a compound
of the invention has a ium enrichment factor for each deuterium atom of at least 3500
(52.5% deuterium incorporation at each ium atom), at least 4000 (60% deuterium
incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium),
at least 5500 (82.5% deuterium incorporation), at least 6000 (90% ium incorporation),
at least 6333.3 (95% ium incorporation), at least 6466.7 (97% deuterium
incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5%
deuterium incorporation).
ium labeled compounds can be prepared using any of a variety of art-
recognized techniques. For example, deuterium labeled compounds of formula I or II or the
compounds listed in Table 1 can generally be prepared by carrying out the procedures
disclosed in the Schemes and/or Examples described herein, by tuting a readily
available deuterium d reagent for a non—deuterium d reagent.
A compound of the invention or a pharmaceutically acceptable salt or solvate thereof
that contains the aforementioned deuterium atom(s) is within the scope of the invention.
Further, substitution with deuterium, z'. e. can afford certain eutic advantages
, 2H,
resulting from greater metabolic stability, for example, increased in vivo half—life and/or
reduced dosage requirements.
In one aspect, the present invention relates to a method of synthesizing a compound of
the invention or a pharmaceutically acceptable salt or e thereof
Pharmaceutical Compositions of the Invention
The t invention relates to ceutical compositions sing a compound
of the invention as an active ingredient. In one aspect, the invention provides a
pharmaceutical composition comprising at least one compound of formula I or II, or a
pharmaceutically acceptable salt or solvate thereof and one or more pharmaceutically
acceptable carriers or ents. In one aspect, the invention provides a pharmaceutical
composition comprising at least one compound selected from Table 1. In a further aspect, the
invention provides a pharmaceutical composition comprising at least one compound selected
from compounds A1, A2, and A3. In a further , the invention provides a
pharmaceutical ition comprising at least one compound selected from compounds A1
and A2. In a further aspect, the invention provides a pharmaceutical composition sing
nd Al.
As used herein, the term “composition” is intended to encompass a product
comprising the specified ingredients in the specified amounts, as well as any product which
s, directly or indirectly, from combination of the specified ingredients in the specified
amounts.
The compounds of the invention can be formulated for oral administration in forms
such as tablets, capsules (each of which es sustained e or timed release
formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups and emulsions.
The compounds of the invention can also be formulated for intravenous (bolus or in—fusion),
intraperitoneal, topical (e. g., ocular eye-drop), subcutaneous, intramuscular or transdermal
(e. g., patch) administration, all using forms well known to those of ordinary skill in the
pharmaceutical arts. Preferably, compounds of the invention for the treatment of macular
degeneration, DR, DME, or macular edema following RVO, are formulated for topical
administration, for example, in the form of eye-drops.
For topical ocular administration, the compositions are provided as ophthalmic
formulation comprising a compound of the t invention in concentration between about
0.01 and about 5 weight percent, preferably between about 0.1 and about 5.0 weight percent,
more preferably n about 0.5 and about 5.0 weight percent, and most preferably
between about 0.8 and about 3.0 weight percent.
The ophthalmic formulation of the present invention may be in the form of an
aqueous solution comprising an aqueous vehicle.
The s vehicle component of the ophthalmic formulation may comprise water
and at least one ophthalmically acceptable excipient. Preferably, the aqueous vehicle
comprises a on of the one or more ophthalmically acceptable excipients in water.
Suitable ophthalmically acceptable excipients include those selected from the group
ting of a solubility enhancing agent, chelating agent, preservative, tonicity agent,
viscosity/suspending agent, , and pH ing agent, and a mixture thereof.
Preferably, the ophthalmically able excipient is ed from the group consisting of a
solubility enhancing agent, chelating agent, preservative, tonicity agent, viscosity/suspending
agent, and pH modifying agent, and a mixture thereof
Any suitable ophthalmically acceptable solubility enhancing agent can be used.
Examples of a solubility ing agent include cyclodextrin, such as those selected from
the group consisting of hydroxypropyl-[3—cyclodextrin, methyl-[3-cyclodextrin, ly
methylated—[3—cyclodextrin, ethylated-B-cyclodextrin, triacetyl—[3-cyclodextrin, peracetylated-
[3-cyclodextrin, carboxymethyl-[3-cyclodextrin, hydroxyethyl—[3-cyclodextrin, 2-hydroxy—3-
(trimethylammonio)propyl-[3—cyclodextrin, yl—[3—cyclodextrin, sulphated [3-cyclodextrin
(S-B-CD), maltosyl-[3—cyclodextrin, [3-cyclodextrin sulfobutyl ether, branched-[3—cyclodextrin,
ypropyl-y-cyclodextrin, randomly ated-y-cyclodextrin, and trimethyl—ycyclodextrin
, and mixtures thereof. Preferably, solubility enhancing agent includes [3-
cyclodextrin sulfobutyl ether, hyrdoxypropyl—[3-cyclodextrin, sulphated [3-cyclodextrin (S-[3-
CD), and maltosyl-[3-cyclodextrin, and es thereof. [3-cyclodextrin sulfobutyl ether is a
particularly preferred solubility enhancing agent. The solubility enhancing agent(s) may be
added in an amount of about 1 to about 20 wt%, preferably about 1 to about 10 wt%, and
more preferably about 5 to about 10_ wt%.
Any suitable ophthalmically acceptable chelating agent can be used. Examples of a
suitable ophthalmically acceptable chelating agent include those selected from the group
consisting of ethylenediaminetetraacetic acid and metal salts thereof, um edetate,
trisodium edetate, and tetrasodium e, and mixtures thereof. Disodium edetate is a
particularly preferred chelating agent. The chelating agent(s) may be added in an amount of
about 0.001 to about 0.05 wt%, ably about 0.001 to about 0.02 wt%, more preferably
about 0.002 to about 0.01 wt%, and most ably about 0.002 to about 0.005 wt%.
Preferably, the aqueous vehicle includes a preservative. Preferred vatives
include those selected from the group consisting of quaternary ammonium salts such as
benzalkonium s (preferably benzalkonium chloride), chlorhexidine gluconate,
benzethonium chloride, cetyl pyridinium chloride, benzyl bromide, phenylmercury nitrate,
phenylmercury acetate, phenylmercury neodecanoate, merthiolate, methylparaben,
propylparaben, sorbic acid, potassium sorbate, sodium benzoate, sodium propionate, ethyl p—
hydroxybenzoate, propylaminopropyl biguanide, and butyl-p-hydroxybenzoate, sorbic acid,
and mixtures thereof More preferably, the preservative is a quaternary ammonium salt such
as benzalkonium halides rably benzalkonium chloride), chlorhexidine gluconate,
benzethonium chloride, cetyl pyridinium chloride, potassium sorbate, sodium benzoate, ethyl
p-hydroxybenzoate, butyl p-hydroxybenzoate, or propylaminopropyl biguanide, or mixtures
thereof. Propylaminopropyl biguanide is an especially red preservative. The
preservative(s) may be used in an amount of about 0.00001 to about 00001 wt%, preferably
about 0.00001 to about 0.00008 wt%, and more preferably about 0.00002 to about 0.00005
wt%.
The aqueous vehicle may also include a ty agent to adjust the tonicity (osmotic
pressure) in order to achieve an lmically compatible formulation. The tonicity agent
can be selected from the group consisting of a glycol (such as propylene glycol, diethylene
glycol, triethylene glycol), glycerol, dextrose, glycerin, mannitol, potassium chloride, and
sodium chloride, and a mixture thereof. Preferably, the tonicity agent is selected from the
group consisting of glycerin, mannitol, ium chloride, and sodium chloride. More
preferably mannitol and/or sodium chloride (and most preferably a mixture f) are
employed. The tonicity agent(s) may be used in an amount of about 0.05 to about 8 wt%,
preferably about 0.1 to about 6 wt%, more ably about 0.1 to about 4 wt%, and most
preferably about 0.2 to about 4 wt%.‘
When a mixture of mannitol and sodium chloride is used as tonicity , preferably
the weight ratio of ol : sodium chloride is about 4:1 to about 15:1, more preferably
about 6:1 to about 14:1, or 8:1 to about 14:1 and particularly about 10:1 to about 12:1. If
mannitol alone is used as the tonicity agent, it is preferably used in an concentration of about
4.5 to about 6.5 wt%, and more preferably in a concentration of about 5.0 to about 5.5 wt%.
If sodium chloride alone is used as the tonicity agent, it is used in a concentration of about
0.05 to about 8 wt%, preferably about 0.1 to about 6 wt%, more preferably about 0.1 to about
4 wt%, and most preferably about 0.2 to about 4 wt%.
The aqueous vehicle preferably also contains a viscosity/suspending agent. Suitable
viscosity/suspending agents include those selected from the group ting of cellulose
derivatives, such as methyl cellulose, ethyl cellulose, hydroxyethylcellulose, polyethylene
glycols (such as polyethylene glycol 300, polyethylene glycol 400), carboxymethyl cellulose,
hydroxypropylmethyl ose, and cross—linked acrylic acid polymers (carbomers), such as
polymers of acrylic acid cross—linked with polyalkenyl ethers or divinyl glycol (Carbopols -
such as Carbopol 934, Carbopol 934P, Carbopol 971, Carbopol 974 and Carbopol 974P), and
a mixture thereof. In preferred embodiments of the present invention, the
viscosity/suspending agent is a carbomer, more preferably Carbopol 974P. The
ity/suspending agent(s) may be t in an amount of about 0.05 to about 2 wt%,
preferably 0.1 to about 1 wt%, more ably about 0.2 to about 0.8 wt%, and most
preferably about 0.3 to about 0.5 wt%.
In order to adjust the formulation to an ophthalmically acceptable pH (typically a pH
range of about 5.0 to about 9.0, more preferably about 5.5 to about 8.5, particularly about 6.0
to about 8.5, about 7.0 to about 8.5, about 7.2 to about 7.7, about 7.1 to about 7.9, or about
7.5 to about 8.0), the ation may contain a pH modifying agent. The pH modifying
agent is typically a l acid or metal hydroxide base, ed from the group of
potassium hydroxide, sodium hydroxide, and hloric acid, and mixtures thereof, and
preferably sodium hydroxide and/or hydrochloric acid. These acidic and/or basic pH
modifying agents are added to adjust the formulation to the target ophthalmically able
pH range. Hence it may not be necessary to use both acid and base — ing on the
formulation, the addition of one of the acid or base may be sufficient to bring the mixture to
the desired pH range.
The aqueous vehicle may also contain a buffering agent to stabilize the pH. When
used, the buffer is selected from the group consisting of a phosphate buffer (such as sodium
dihydrogen phosphate and disodium hydrogen phosphate), a borate buffer (such as boric acid,
or salts thereof including disodium tetraborate), a citrate buffer (such as citric acid, or salts
thereof including sodium citrate), and s-aminocaproic acid, and mixtures thereof. The buffer
s) may be present in an amount of about 0.05 to about 5 wt%, preferably 0.1 to about 5
wt%, more preferably about 0.2 to about 5 wt%, and most preferably about 0.5 to about 5
wt%.
The ophthalmic formulation for topical administration to the eye may further
se a wetting agent. In any embodiment of the present invention the wetting agent is
preferably a non-ionic g agent. More preferably, the g agent is water soluble or
swellable. Most preferably the wetting agent is water soluble. “Water soluble” is to be
understood in the manner used in stande texts such as the “Handbook of Pharmaceutical
ents” (Raymond C Rowe, Paul J Sheskey and Sian C Owen, Fifth Edition,
Pharmaceutical Press and American Pharmacists Association 2006). Suitable classes of
wetting agents include those selected from the group consisting of polyoxypropylene-
yethylene block copolymers (poloxamers), polyethoxylated ethers of castor oils,
polyoxyethylenated sorbitan esters (polysorbates), polymers of oxyethylated octyl phenol
(Tyloxapol), polyoxyl 40 stearate, fatty acid glycol esters, fatty acid yl esters, sucrose
fatty esters, and polyoxyethylene fatty esters, and mixtures thereof.
c es of suitable g agents include those selected from the group
consisting of: polyoxyethylene—p0lyoxypropylene block copolymers (poloxamers) such as:
polyoxyethylene (160) ypropylene (30) glycol [Pluronic F68], polyoxyethylene (42)
polyoxypropylene (67) glycol [Pluronic P123], polyoxyethylene (54) polyoxypropylene (39)
glycol [Pluronic P85], polyoxyethylene (196) polyoxypropylene (67) glycol [Poloxamer 407,
Pluronic F127], polyoxyethylene (20) polyoxypropylene (20) glycol [Pluronic L44],
yethylenated sorbitan esters (polysorbates) such as poly(oxyethylene)sorbitan
monopalmitate (polysorbate 40), poly(oxyethylene)sorbitan monostearate (polysorbate 60),
poly(oxyethylene)sorbitan tristearate (polysorbate 65), poly(oxyethylene) an
monooleate (polysorbate 80), poly(oxyethylene) sorbitan monolaurate, poly(oxyethylene)
sorbitan trioleate, polyethoxylated ethers of castor oils such as polyoxyethylene hydrogenated
castor oil 10, polyoxyethylene hydrogenated castor oil 40, polyoxyethylene enated
castor oil 50 and polyoxyethylene liydrogenated castor oil 60, polyoxyl 40 stearate, sucrose
fatty esters, and polyoxyethylene fatty , and mixtures thereof.
Preferably, the wetting agent is selected from the group consisting of:
polyoxyethylene-p0lyoxypropylene block copolymers (poloxamers) such as: polyoxyethylene
(160) polyoxypropylene (30) glycol nic F68], polyoxyethylene (42) polyoxypropylene
(67) glycol [Pluronic P123], polyoxyethylene (54) polyoxypropylene (39) glycol [Pluronic
P85], polyoxyethylene (196) polyoxypropylene (67) glycol [Poloxamer 407, Pluronic F127],
and polyoxyethylene (20) polyoxypropylene (20) glycol [Pluronic L44], polyoxyethylenated
sorbitan esters (polysorbates) such as poly(oxyethylene)sorbitan monopalmitate (polysorbate
40), poly(oxyethylene)sorbitan monosteaxate (polysorbate 60), poly(oxyethylene)sorbitan
tristearate (polysorbate 65), poly(oxyethylene) an monooleate (polysorbate 80),
poly(oxyethylene) sorbitan monolaurate, and poly(oxyethylene) sorbitan trioleate and
mixtures thereof.
More preferably, the wetting agent is a polyoxyethylene-polyoxypropylene block
copolymer (poloxamer). Examples of suitable poloxamers include: polyoxyethylene (160)
polyoxypropylene (30) glycol [Pluronic F68], polyoxyethylene (42) polyoxypropylene (67)
glycol [Pluronic P123], polyoxyethylene (54) polyoxypropylene (39) glycol [Pluronic P85],
polyoxyethylene (196) polyoxypropylene (67) glycol [Poloxamer 407, Pluronic F127] and
polyoxyethylene (20) polyoxypropylene (20) glycol [Pluronic L44] or a mixture thereof.
Further preferred are wetting agents selected from the group consisting of
polyoxyethylene (42) polyoxypropylene (67) glycol [Pluronic PI 23], polyoxyethylene (54)
polyoxypropylene (39) glycol [Pluronic P85], polyoxyethylene (196) polyoxypropylene (67)
glycol amer 407, Pluronic F127] and mixtures thereof.
An especially red g agent is polyoxyethylene (196) polyoxypropylene
(67) glycol [Poloxamer 407, Pluronic F127].
Particularly preferred formulations for topical administration to the eye of the t
invention comprise a compound of the t ion, a lity enhancing agent, a
cheating agent, a preservative, a tonicity agent, a viscosity/suspending agent, a , and a
pH modifying agent. More particularly preferred formulations are comprised of an aqueous
solution of a B-cyclodextrin, a borate salt, boric acid, sodium chloride, disodium edetate, and
propylaminopropyl biguanide.
In one aspect, the ophthalmic formulation of the present invention is in the form of a
on, such as one of the following:
on Comnosition
a com nound ofthe ion
Solution Composition
a com ound of the invention
a solubility enhancing agent
a buffering a ent
.05 mg
on Composition I II III IV
a compound of the invention 2.5 g 1.0 g
g 10L 5 g
1.05 g 1.05 g
fi—O 285 g
2.5 mg 2.5 mg 2.5 mg
0.03 mg 0.03 mg 0.03 mg 0.03 mg
100 ml 100 ml 100 nil 100 ml
The ophthalmic formulation of the present invention may also be in the form of a gel
or a semi—gel, or both; a jelly; a suspension; an on; an oil; an ointment; a cream; or a
spray.
The ophthalmic gel, semi-gel, jelly, suspension, emulsion, oil, ointment, cream, or
spray may contain various additives incorporated ordinarily, such as ing agents (e.g,
phosphate buffers, borate buffers, citrate buffers, tartrate buffers, acetate buffers, amino
acids, sodium acetate, sodium citrate and the like), tonicity agents (e.g., saccharides such as
sorbitol, glucose and mannitol, polyhydric alcohols such as glycerin, concentrated glycerin,
PEG and propylene glycol, salts such as sodium chloride), preservatives or antiseptics (e. g.,
benzalkonium chloride, benzatkonium chloride, P-oxybenzoates such as methyl p-
oxybenzoate or ethyl p-oxybenzoate, benzyl alcohol, phenethyl alcohol, sorbic acid or its salt,
thimerosal, chlorobutanol and the like), solubilizing enhancing agents (e. g. , cyclodextrins and
their derivative, water-soluble polymers such as polyvinyl pyrrolidone, surfactants such as
tyloxapol, polysorbates), pH modifiers (e.g, hydrochloric acid, acetic acid, phosphoric acid,
sodium hydroxide, potassium hydroxide, ammonium hydroxide and the like), thickening
agents (e. g., HEC, hydroxypropyl cellulose, methyl cellulose, HPMC, carboxymethyl
cellulose and their salts), chelating agents (e. g., sodium edetate, Ssdium citrate, condensed
sodium phosphate) and the like. Each of these ves may be in the amount or
concentration similar to those described for the ophthalmic formulation in the form of a
solution above.
Furthermore the compounds of the invention may be formulated for l
administration by oration into novel ophthamlic ations including but not limited
to: microemulsions, liposomes, niosomes, gels, hydrogel, nanoparticles, and nanosuspension.
1. Microemulsions
Microemulsions are dispersion of water and oil tated by a combination of
surfactant and cosurfactant in a manner to reduce interfacial tension. These systems are
y characterized by higher thermodynamic stability, small t size (approximately
100 nm) and clear appearance. Their transparent appearance is due to the high level of
dispersion of the internal phase, and the size of it ranges from 100-1000 angstroms.
Processes for forming microemulsions le for use in ophthalmic formulations are
descrived in Vandamne TF. Prog Retinal Eye Res 2002; 21 :15—34, which is incorporated by
reference.
2. Liposomes
Liposomes are lipid vesicles ning aqueous core and have been widely exploited
in ocular delivery for various drug substances. Depending on the nature of the lipid
composition selected, liposomes can provide extended release of the drug.
3. Niosomes
Niosomes are bilayered structural es made up of ic surfactant and are
capable of encapsulating both lipophilic and hydrophilic nds. They can release the
drug independent of pH and enhance ocular bioavailability. Niosomes are microscopic
lamellar structures that are formed on the admixture of nonionic surfactant of the alkyl or
diakyl polyglycerol ether class and cholesterol with subsequent hydration in aqueous media.
Structurally niosomes are r to liposomes, in that they are also made up of a bilayer.
However, the bilayer in the case of nisomes is made up of nonionic surface—active agents
rather than phospholipids as in the case of liposomes. Niosomes may be unilamellar or
multilamellar depending on the method used to e them. They are e of entrapping
hydrophilic and hydrophobic solutes. They s great stability and lack many
disadvantages associate with mes such as high cost and the variable purity of
phospholipids. The properties of niosomes and process for preparing them are well known in
the art, see e.g., Wagh VD et al., J Pharm Res 2010; 3(7):1558—1563; Kaur H et 61]., Int J
Pharm Sci Rev Res 2012; 15(1): 1 13——l20, each of which is incorporated by reference.
4. Gels
Ophthalmic gels are composed of mucoadhesive polymers that e localized
delivery of an active ingredient to the eye. Such polymers have a ty known as
bioadhesion, meaning attachment of a drug carrier to a specific biological tissue. These
polymers are able to extend the contact time of the drug with the biological s and
thereby improve ocular bioavailability. The choice of the polymer plays a al role in the
release kinetics of the drug from the dosage form. Several bioadhesive polymers are
available with varying degree of mucoadhesive performance. Some examples are
carboxymethylcellulose, carbopol, polycarbophil, and sodium alginate. The use of gel
formulations in ocular drug deliver has been reviewed in Ali Y et 51]., Adv Drug Deliv Rev
2006; 58: 268, which is incorporated by reference.
. Hydrogels
Hydrogels are three-dimensional, hydrophilic, polymeric networks capable of taking
in large amounts of water or biological fluids. Residence time can be significantly enhanced
with a hydrogel formulation. The gelation can be ed by changing ature and pH.
Poloxamers, the most widely used polymer, contains the hydrophobic part in the centre
surrounded by a hydrophilic part. Though they are widely employed to enhance the residence
time. Recent ctives in the use of hydrogels in ocular drug deliver are described by
a R, Jwala J, Boddu SHS, Mitra AK. Pharm Res. 2009; 26(5):l 197—1216 which is
incorporated by reference.
6. Nanoparticles
Nanoparticles are defined as particles with a diameter of less than 1 um, comprising
of various biodegradable or non biodegradable polymers, lipids, phospholipids or metals.
They can be classified as nanospheres or nanocapsules depending upon whether the drug has
been uniformly dispersed or coated within polymeric material. The uptake and distribution of
nanoparticles is dependent on their size. The use of nanoparticles in ocular drug delivery has
WO 24302
recently been reviewed by Hing er al., Int. J. Ophthalmol 2013; 6:390—396, which is
incorporated by reference.
7. Nanosuspensions
Nanosuspensions are defined as sub—micron colloidal s that consist of poorly
water soluble drugs suspended in an appropriate dispersion medium stabilized by tants.
Usually, spensions consist of colloidal carriers like polymeric resins which are inert in
nature. Nanosuspensions enhance drug solubility and thus bioavailability. Unlike
microemulsions, nanosuspensions are non—irritant. Charge on the surface of nanoparticles
facilitates their adhesion to the cornea. The use of nanosuspensions in drug delivery is
reviewed in Rabinow, Nature Rev Drug Disc 2004; 785—796, which is incorporated by
reference.
The compounds of the present invention can also be administered in the form of a
formulation suitable for ocular topical delivery. Detailed descriptions of formulation suitable
for ocular topical delivery are bed in JD. Bartlett and S. D. Jaanus, “Clinical Ocular
Pharmacology”, 2008, Elsevier Health Sciences, which is incorporated by reference.
The compounds of the ion may also be coupled with soluble polymers as
targetable drug carriers. Such rs can include polyvinylpyrrolidone, pyran copolymer,
polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspartamide-phenol, and
polyethyleneoxide-polylysine substituted with palmitoyl residues. Furthermore, the
nds ofthe invention may be coupled to a class of biodegradable polymers useful in
ing lled release of a drug, for example, ctic acid, polyglycolic acid,
copolymers of polylactic and polyglycolic acid, polyepsilon actone, polyhydroxy
butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and
crosslinked or amphipathic block copolymers of hydrogels.
The present ion also provides a pharmaceutical composition comprising a
compound ofthe invention or a pharmaceutically acceptable salt or solvate thereof, and a
pharmaceutically acceptable carrier or excipient, and further an active ingredient ed
from the group ting of a) an antagonist of integrin OLSBI, b) a cytotoxic/antiproliferative
agent, c) an inhibitor of epidermal-derived, fibroblast-derived, or platelet-derived growth
, d) an inhibitor of VEGF, e) an inhibitor of Flk—l/KDR, Flt—l, Tck/Tie-2, or Tic-l, and
f) an inhibitor of phosphoinositide 3-kinase, and a mixture thereof
The present invention further provides a pharmaceutical composition comprising a
compound of the invention or a pharmaceutically acceptable salt or solvate thereof, and a
ceutically acceptable carrier or excipient, and further an active ingredient selected
WO 24302
from the group consisting of a) an antagonist of integrin 0L5Bl, b) a xic/antiproliferative
agent, c) an inhibitor of epidermal-derived, fibroblast—derived, or platelet-derived growth
s, d) an inhibitor of VEGF, and e) an inhibitor of phosphoinositide 3—kinase, and a
mixture f.
Nonlimiting examples of antagonists of integrin a5Bl are (S)—2—((R)—2—((S)—2-((S)—2-
((S)—l ~acetylpyrrolidine-2—carboxamido)—3—( l H—imidazol-5—yl)propanamido)—3—
hydroxypropanamido)mercaptopropanamido)succinamide, and JSM6427, described in
es, R. et 61]., J. Med. Chem. 2007, 50:3786—3794, herein incorporated by reference.
Nonlimiting examples of cytotoxic/antiproliferative agents are taxol, vincristine,
vinblastine, and doxorubicin.
Nonlimiting examples of inhibitors of epidermal—derived, ast—derived, or
platelet-derived growth s are pazopanib, and sunitinib,
Nonlimiting examples of inhibitors of vascular endothelial derived growth factor
(VEGF) 'are bevacizumab and ranibizumab,
Nonlimiting examples of inhibitors of phosphoinositide se are indelalisib and 2—
lin-4—yl—8—phenylchroman-4—one.
Methods of Use
Compounds of the invention typically display submicromolar inhibitory activity for
the integrins av, such as OMB and (WM. Inhibiting the function of OMB and aVBS integrins
prevents endothelial cell proliferation. Endothelial cell proliferation can result in deleterious
neovascularization or angiogenesis, particularly choroidal cularization in
the choriocapillaris, through Bruch’s membrane, ultimately leading to blood and protein
e below the macula. Bleeding, leaking, and scarring from these blood vessels
eventually cause irreversible damage to the photoreceptors and rapid vision loss if left
untreated.
Diabetic retinopathy, a closely related condition, is the result of microvascular retinal
changes. Hyperglycemia-induced intramural pericyte death and thickening of the basement
ne lead to incompetence of the vascular walls in the retina, which s the blood—
retinal barrier and makes the retinal blood vessels more permeable. Damaged blood vessels
leak fluid and lipids onto the macula, the part of the retina that provides us with detailed
vision, causing the macula to swell. Eventually this can progress to develop a condition
called macular edema.
Accordingly, AMD, DR, DME, and macular edema ing central retinal vein
occlusion (thrombosis) can be treated or prevented through administration (e. g. , topical
administration) of the compounds or pharmaceutical itions of the present invention.
The present ion provides a method of treating or preventing a disease or
condition in a subject, comprising administering to a subject in need thereof a therapeutically
effective amount of a compound of the invention or a pharmaceutically acceptable salt or
solvate thereof or a therapeutically effective amount of a pharmaceutical composition of the
invention. In one aspect, the invention provides treating a disease or condition. In one
aspect, the invention provides preventing a disease or condition.
In one aspect, the compound or pharmaceutical composition of the invention is
administered topically. In a further , the compound or pharmaceutical composition of
the invention is administered as an ophthalmic on. In another aspect, the compound or
ceutical composition of the invention is administered as an ophthalmic emulsion,
suspension, gel, or semi-gel. In another aspect, the nd or pharmaceutical ition
of the ion is administered as an ophthalmic jelly, oil, ointment, cream, or spray.
The compounds or pharmaceutical compositions of the invention are administered in
dosages effective to inhibit the function of avB3 and/or avBS ins and thus treat or
prevent a disease ion mediated by the avB3 and/or avBS integrin.
The present invention provides a method of treating or preventing a disease or
condition mediated by an av integrin in a subject, comprising administering to a subject in
need thereof a therapeutically effective amount of a compound of the invention or a
pharmaceutically acceptable salt or solvate thereof or a therapeutically effective amount of a
pharmaceutical composition of the invention. In one aspect, the disease or ion is a
disease or ion in which angiogenesis is involved. In a further aspect, the disease or
condition is a disease or condition in which ocular angiogenesis is involved.
The present invention also provides a method of treating or preventing an avB3
and/or avBS integrin—mediated disease or condition in a subject, comprising administering to
a subject in need thereof a therapeutically effective amount of a compound of the invention or
a pharmaceutically able salt or e thereof or a therapeutically effective amount of
a ceutical ition of the ion. In one aspect, the disease or ion is a
disease or condition in which ocular angiogenesis is involved. In one aspect, the disease or
condition is macular degeneration. In one aspect, the disease or condition is age—related
macular degeneration (AMD). In one aspect, the disease or condition is diabetic retinopathy
WO 24302
(DR). In one aspect, the disease or condition is ic macular edema (DME). In one
aspect, the disease or condition is macular edema following l vein occlusion (RVO).
The present invention further provides a method of treating or preventing AMD, DR,
DME, or r edema following RVO, comprising administering to a subject in need
thereof, a therapeutically ive amount of a compound of the invention or a
pharmaceutically acceptable salt or solvate thereof or a therapeutically effective amount of a
pharmaceutical composition of the invention. In one aspect, the invention provides treating
AMD, DR, DME, or macular edema following RVO. In one aspect, the ion provides
preventing AMD, DR, DME, or macular edema following RVO.
The present invention further provides a method of treating or preventing a disease or
condition in a subject, comprising stering to a subject in need thereof a therapeutically
effective amount of a compound of the invention or a pharmaceutically acceptable salt or
e thereof or a therapeutically effective amount of a ceutical composition of the
ion, in combination with a second therapy for treating or preventing the disease or
condition. In one aspect, the disease or condition is mediated by an (iv integrin. In a further
aspect, the disease or condition is mediated by an (va3 and/or ochS integrin. In one aspect,
the disease or condition is a disease or condition in which angiogenesis is involved. In a
further aspect, the disease or condition is a disease or condition in which ocular angiogenesis
is involved. In one aspect, the second therapy comprises administration of one or more of the
following: a) an antagonist of integrin (XSBI, b) a cytotoxic/antiproliferative agent, c) an
inhibitor of epidermal-derived, fibroblast-derived, or platelet-derived growth factor, d) an
inhibitor of VEGF, e) an inhibitor of Flk-l/KDR, Flt-l, Tck/Tie-2, or Tic-1, and f) an
tor of phosphoinositide 3-kinase, and a mixture thereof. In a further aspect, the second
therapy comprises administration of one or more of the following: a) an nist of
integrin (XSBI, b) a cytotoxic/antiproliferative agent, c) an tor of epidermal-derived,
fibroblast-derived, or platelet-derived growth factor, d) an inhibitor of VEGF, and e) an
inhibitor of phosphoinositide 3-kinase, and a mixture thereof. In a further aspect, the second
therapy comprises administration of an inhibitor of VEGF. In a further , the VEGF
tor is zumab or ranibizumab.
The second therapy can be administered via any administration routes, including oral
administration in forms such as tablets, es (each of which includes sustained release or
timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups
emulsions, enous administration (bolus or in—fusion), intraperitoneal administration,
topical administration (e.g, ocular eye-drop), subcutaneous administration, intramuscular
administration, transdermal (e.g., patch) administration, and intravitreal administration. In
one aspect, the second therapy is administered through intravitreal injection.
Administration of the second therapy in combination typically is carried out over a
defined time period (usually minutes, hours, days or weeks depending upon the combination
selected). “Combination y” may be, but generally is not, intended to encompass the
administration of two or more of these therapeutic agents as part of separate monotherapy
ns that incidentally and arbitrarily result in the combinations of the present invention.
“Combination therapy” is intended to embrace administration of these therapeutic agents in a
sequential , wherein each therapeutic agent is administered at a different time, as well
as administration of these eutic agents, or at least two of the therapeutic agents, in a
substantially simultaneous manner.
In accordance with the method ofthe invention, the individual ents of the
combination can be administered separately at different times during the course of therapy or
concurrently in divided or single combination forms. The instant invention is therefore to be
understood as embracing all such regimens of simultaneous or alternating treatment, and the
term “administering” is to be interpreted accordingly. It will be understood that the scope of
combinations of the compounds of the invention with other agents useful for treating (xv
integrin-mediated ions includes in principle any combination with any pharmaceutical
composition useful for treating macular ration, DR, DME, or macular edema
following RVO. When the method of the invention is a combination treatment of a
formulation of the present invention topically administered to the eyes and an anti-VEGF
protein or aptamer, the procedures, dosages and frequencies of the anti-VEGF protein or
aptamer are as described in the e s for those agents.
The dosage regimen utilizing the compounds of the invention is selected in
accordance with a y of factors ing type, species, age, weight, sex and medical
condition of the patient; the severity of the condition to be treated; and the particular
compound or salt thereof employed. An ordinary skilled physician, veterinarian or clinician
can readily ine and prescribe the effective amount of the drug ed to prevent,
r or arrest the progress of the condition.
In the methods of the invention, the compounds herein described in detail can form
the active ingredient, and are typically administered in admixture with le
pharmaceutical diluents, excipients or carriers (collectively referred to herein as “carrier”)
ly selected with respect to the intended topical administration to the eye and consistent
with tional pharmaceutical practices.
For purposes of the invention, the following definitions will be used (unless sly
stated otherwise):
“A nd of the invention3, ‘6 ‘6
, compounds of the invention9, a compound of the
present invention”, or “compounds of the present invention” refers to a nd(s)
disclosed herein, e.g, a compound(s) of the invention includes a compound(s) of any of the
ae described herein including formula I and 11 and/or a compound(s) explicitly
disclosed herein. Whenever the term is used in the context of the invention it is to be
understood that the reference is being made to the free base and the corresponding
pharmaceutically acceptable salts or solvates f, provided that such is possible and/or
appropriate under the stances.
“Pharmaceutical” or “pharmaceutically acceptable” when used herein as an adjective,
means substantially non-toxic and ntially non-deleterious to the recipient.
By “pharmaceutical composition” it is further meant that the carrier, diluent, solvent,
excipient, and salt must be compatible with the active ingredient of the formulation (e.g., a
compound of the invention). It is understood by those of ordinary skill in this art that the
terms “pharmaceutical formulation” and “pharmaceutical composition” are generally
interchangeable, and they are so used for the purposes of this application.
“Solution” refers to a clear, homogeneous liquid dosage form that contains one or
more chemical substances ved in a solvent or mixture of mutually miscible solvents.
Because les of a therapeutic agent nce in solution are uniformly dispersed, the
use of solutions as dosage forms generally provides assurance of uniform dosage upon
administration and good accuracy when the solution is diluted or ise mixed.
“Solution” as disclosed herein contemplates any ions based on the current state of the
art or variations achieved by one skilled in the art.
“Suspension” refers to a liquid dosage form that ns solid particles dispersed in a
liquid vehicle. “Suspension” as disclosed herein contemplates any variations based on the
current state of the art or variations achieved by one skilled in the art.
ient” is used herein to include any other compound that is not a therapeutically
or biologically active compound and may be contained in or combined with one or more of
the compounds of the present invention. As such, an excipient should be pharmaceutically or
biologically acceptable or relevant (for e, an excipient should generally be non-toxic
to the subject). “Excipient” includes a single such compound and is also intended to include
a plurality of excipients. For the purposes of the present disclosure the term ient” and
“carrier” are used interchangeably throughout the description of the t application.
“Therapeutically effective amount” refers to that amount of a drug or pharmaceutical
agent that will elicit the biological or medical response of a tissue, system, animal, or human
that is being sought by a cher or clinician.
“Treat,” “treating,” or “treatment” refers to decreasing the symptoms, markers, and/or
any negative effects of a disease or ion in any appreciable degree in a subject who
currently has the disease or ion. In some embodiments, treatment may be administered
to a subject who exhibits only early signs of a e or condition for the purpose of
decreasing the risk of developing the disease or condition. In some embodiments, “Treat,”
“treating,” or “treatment” refers to amelioration of one or more symptoms of a e or
condition. For example, amelioration of one or more ms of a disease or condition
includes a decrease in the severity, frequency, and/or length of one or more symptoms of a
disease or condition.
“Prevent,” “prevention,” or “preventing” refers to any method to partially or
completely prevent or delay the onset of one or more symptoms or features of a e or
condition. Prevention may be administered to a subject who does not exhibit any sign of a
disease or condition.
“Subject” means a human or animal (in the case of an animal, more typically a
mammal). In one aspect, the subject is a human.
The term “symptom” is defined as an indication of disease, illness, injury, or that
something is not right in the body. Symptoms are felt or noticed by the individual
experiencing the symptom, but may not easily be noticed by others. Others are defined as
non-health-care professionals.
“0w integrin antagonist” refers to a compound which binds to and ts or interferes
with the function of either avB3 or avBS, or a compound which binds to and inhibits or
interferes with the function of both (va3 and (vaS (i. e., a dual (va3/0LVB5 antagonist). The
compounds bind to the receptors as antagonists, blocking or interfering with the binding of
the native agonist, such as vitronectin, while not provoking a ical response themselves.
“Bone resorption” refers to the process by which osteoclasts degrade bone.
“Alkyl” refers to straight chain or branched alkyl of the number of carbon atoms
specified (e. g., C1-C4 , or any number within this range (methyl, ethyl, propyl, i-propyl,
butyl, i-butyl, t-butyl, etc).
“Alkoxy” refers to straight chain or branched alkoxides of the number of carbon
atoms specified (e. g., C1-C6 alkoxy), or any number within this range (methoxy, ,
propoxy, i-propoxy, butoxy, i-butoxy, t-butoxy, etc.)
cyclic ring” refers to saturated cycloalkyl of the number of carbon atoms
specified (i.e., C3 or C4), such as cyclopropyl and cyclobutyl.
ocyclic ring” refers to saturated heterocyclic ring of the number of carbon
atoms specified (i.e., C3 or C4), further comprising one additional heteroatoms selected from
N, O, and S.
The term “about” refers to a range of values which can be 15%, 10%, 8%, 5%, 3%,
2%, 1%, or 0.5% more or less than the specified value. For example, “about 10%” can be
from 8.5% to 11.5%. In one embodiment, the term “about” refers to a range of values which
are 5% more or less than the ed value. In another embodiment, the term “about” refers
to a range of values which are 2% more or less than the ed value. In another
embodiment, the term “about” refers to a range of values which are 1% more or less than the
specified value.
EXAMPLES
Example 1. Synthesis of (S)—3-(6-(difluoromethoxy)-pyridineyl)-3—(2—oxo(3—(5, 6, 7, 8—
tetrahydro—1, 8—naphthyridin-2—yl)propyl)imidazolidin—1-yl) propanoic acid (Compound A1)
Compound A1 is made using a convergent sis scheme as shown in Scheme 1:
fragment 6b is reacted with nt 9 to form compound 10, which is further reacted in
three steps to form Compound A1.
Synthesis of fragment 6b
tert-butyl 2-oxopyrrolidine-l-carboxylate (2a): To a stirred solution of compound
1a (100 g, 117 mmol, 1.0 equiv.) in DCM, (Boc)20 (25.5 g, 117 mmol, 1.00 equiv.) and
DMAP (0.022 g, 0.180 mmol, 0.001 ) were added at RT and stirred for 12 h. After
consumption of the starting material (monitored by TLC), volatiles were removed under
reduced pressure to afford compound 2a (196 g, 90.3%) as a brown syrup.
TLC: 50% EtOAc/Hexane (Rf: 0.40)
1H NMR (400 MHz, CDC13): 8 3.74 (t, J: 6.8 Hz, 2H), 2.50 (t, J= 8.0 Hz, 2H), 2.01 (t, J:
7.6 Hz,‘2H), 1.52 (s, 9H)
tert—butyl (5—(dimethoxyphosphoryl)—4-oxopentyl)carbamate (321): To a stirred
solution of iPerH (2.99 mL, 21.8 mmol, 1.35 equiv.) in THF, cooled to -10 0C, hexyl lithium
(8.79 mL, 20.0 mmol, 1.24 equiv.) was slowly added. The on mixture was cooled to -
60 °C, dimethylmethyl phosphonate (2.20 mL, 20.9 mmol, 1.29 equiv.) was added and
stirred for 1 h. Then the temperature was raised to —40°C, and compound Za (3.0 g, 16.2
mmol, 1.0 ) was uced to the reaction mixture and stirring was continued for
further 1 h. After consumption of the starting material, 2N H2804 solution (20 mL) was
added slowly to the reaction and stirred at 0°C for 15 minutes. The aqueous layer was
extracted with EtOAc (2 x 25 mL). The combined organic extracts were washed with water
(25 mL), brine (25 ml), dried over NaZSO4, filtered and evaporated under reduced re to
afford compound 33 as a brown liquid (5.0 g, crude).
TLC: 80% EtOAc/Hexane (Rf: 0.30)
1H NMR (400 MHz, Z 6 4.85 (brs, 1H, Exc), 3.80-3.72 (m, 8H), 3.13-3.07 (m, 2H),
2.67 (t, J= 6.8 Hz, 2H), 1.87— 1.76 (m, 2H), 1.43 (s, 9H)
LC—MS: m/z = 308.3 [M+H]+ at RT 2.67 (99.1% purity)
tert-butyl (3-(1, 8-naphthyridin-2—yl)pr0pyl)carbamate (53): To a stirred solution
of compound 421 (0.500 g, 4.09 mmol, 1.0 equiv.) and compound 3a ( 1.26 g, crude, 1.0
equiv.) in MeOH (9.17 mL), 50% NaOH solution (0.314 mL) was added and the reaction
mixture was stirred at 50°C for 10 h. After consumption of the starting material (by TLC),
volatiles were removed, crude residue was diluted with EtOAc (15 mL) and the organic layer
was washed with water (2 x 15 mL). The separated c layer was dried over Na2804,
filtered and concentrated under d pressure to afford brown syrup, which was purified
by column chromatography on neutral alumina (80% EtOAc: Hexane) to provide compound
53 (0.980 g, 83.3%) as an off-white solid.
TLC: EtOAc
1H NMR (500 MHz, CDCl3)Z 6 9.09 (s, 1H), 8.17—8.15 (m,1H), 8.10 (d, J: 8.0 Hz, 1H), 7.45
(t, J: 8.0 Hz, 1H), 7.41 (t, J: 15.0, 1H), 4.76 (brs, 1H, Exc), 3.25-3.21 (m, 2H), 3.09 (t, J:
.0 Hz, 2H), 2.14—2.08 (m, 2H), 1.42 (s, 9H)
LC-MS: m/z = 288 [M—H]' at RT 2.86 (94.7 %)
tert-butyl (3-(5,6,7,8-tetrahydr0-1,8-naphthyridin-Z-yl)pr0pyl)carbamate (S-024):
To a stirred solution of compound 5a (0.25 g, 0.87 mmol, 1.00 equiv.) in MeOH (5 mL),
Rh/C (catalytic, 5 wt %) was added under N2 atmosphere and stirred at RT for 8 h under
en (balloon pressure) atmosphere. After completion of the starting material, the
reaction mixture was filtered through pad of ®, washed with MeOH (5 mL). The
filtrate was evaporated under reduced re to afford compound S-024 (0.18 g, 71.1%) as
a white solid.
TLC: EtOAc
2014/015372
1H NMR (400 MHz, CDCl3): 6 7.05 (d, J= 7.6 Hz, 1H), 6.34 (d, J: 7.2 Hz, 1H), 5.44 (s,
1H), 4.78 (brs, 1H, Exc), 3.41-3.38 (m, 2H), 3.16 (d, J= 6.0 Hz, 2H), 2.68 (t, J: 6.0 Hz,
2H), 2.59 (t, J: 7.6 Hz, 2H), 1.93-1.81(m, 4H), 1.44 (s, 9H)
LC-MS: m/z = 292.3 [M+H]+ at RT 3.41(97.9% purity)
3—(5, 6, 7, 8—tetrahydro-1, 8-naphthyridinyl)propan-1~amine (6b): To a stirred
solution of S-024 (0.25 g, 0.85 mmol, 1.00 equiv.) in DCM (5 mL), cooled to 0°C, TFA (0.13
mL, 1.69 mmol, 2.00 equiv.) was added. The reaction was warmed to RT and d for 4 h.
After consumption of the starting material (by TLC), the reaction mixture was concentrated
under reduced pressure to afford crude compound 6b (0.30 g) as a thick syrup which was
used in the next step without purification.
Synthesis of Fragment 9 and completion of the synthesis
—bromo(difluoromethoxy)pyridine (2): To a stirred solution of compound 1
(4.50 g, 25.8 mmol, 1.0 equiv.) in ous MeCN (80 mL), sodium 2-chloro-2,2-
difluoroacetate (4.89 g, 31.0 mmol, 1.20 equiv.) was added at RT and stirred at 70°C for 48 h.
After consumption of the starting al (by TLC), the reaction mixture was brought to RT
and diluted with NH4Cl solution (30 mL). The aqueous layer was extracted with EtOAc (2 x
40 mL). The combined organic layers were washed with brine on (2 x 50 mL), dried
over anhydrous NaZSO4, filtered and concentrated under reduced pressure to give the crude
compound which was purified by column chromatography (2% EtOAc/hexane) to afford
compound 2 (3.2 g, 57%) as pale yellow syrup.
TLC: 5°/o EtOAc/Hexane (Rf; 0.5) 2
1H NMR (400 MHz, CDCl3): 8 8.25 (d, J= 2.8 Hz, 1H), 7.82 (dd, J= 2.4, 6.4 Hz, 1H), 7.40
(t, J= 72.8 Hz, 1H), 6.83 (d, J= 8.8 Hz,1H)
LC-MS: m/z = 224.7 [M+H]+ at RT 4.22 (98.2% purity)
(E)—tert-butyl 3-(6-(difluoromethoxy)pyridin-3—yl)acrylate (3): To a stirred solution
of tert—butyl acrylate (9.99 g, 78.1 mmol, 3.50 equiv.), Et3N (8.5 mL, 60.2 mmol, 2.70
equiv.), N-methyl pyrrolidine (20 mL), Tritolylphosphine (1.17 g, 3.52 mmol, 0.16 equiv.)
followed by Pd(OAc)2 (0.50 g, 2.22 mmol, 0.09 ) were added. The temperature was
gradually raised to 90°C and compound 2 (5.00 g, 22.3 mmol, 1.0 equiv.) in NMP (10 mL)
was added drop wise and stirred at 90°C for 12 h. After consumption of the starting material
(by TLC), the reaction e was filtered through pad of CELITE® and washed with
EtOAc (50 mL). The combined filtrate was washed with cold water (2 x 50 mL) followed by
NaOCl (50 mL), brine solution (50 mL). The organic layer was dried over ous
, filtered and concentrated under reduced pressure to give the crude residue which
was purified by column tography (3% EtOAc/hexane) to afford compound 3 (4.0 g,
66%) as yellow solid.
TLC: 5% Hexane (Rf: 0.5)
1H NMR (400 MHZ, CDCl3): 6 8.28 (d, J= 2.4 Hz, 1H), 7.88 (dd, J: 2.0, 6.4 Hz, 1H), 7.56
(d, J: 16.0 Hz, 1H), 7.55 (t, J: 45.6 Hz, 1H), 6.91 (d, J: 8.4 Hz, 1H), 6.34 (d, J: 16.0 Hz,
1H), 1.53 (s, 9H)
LC-MS: m/z = 272 [M+H]+ at RT 4.16 (99.5% )
(S)—tert-butyl 3—(benzyl ((R)phenylethyl)amin0)-3—(6-methoxypyridin
yl)pr0panoate (5): To a stirred solution of compound 4 (0.39 g, 1.85 mmol, 2.0 equiv.) in
THF (5 mL), cooled to -30°C, n-BuLi (0.66 mL, 1.65 mmol, 1.79 equiv.) was added and then
cooled to —78°C. Compound 3 (0.25 g, 0.92 mmol, 1.0 equiv.) dissolved in THF (3 mL) was
added to the reaction mixture, stirred for 30 min and quenched with saturated ammonium
chloride. The reaction mixture was extracted with EtOAc (2 x 20 mL). The combined
organic extracts were washed with 10% AcOH, brine solution which was dried over
anhydrous NaZSO4, filtered and concentrated under reduced pressure to give the crude
compound (mixture of 3 and 5, 0.17 g) as thick syrup, which was directly used in the next
step.
TLC: 5% EtOAc/Hexane (Rf: 0.5)
LC-MS: m/z = 483 [M+H]+ at RT 4.66 (75.1% purity)
Synthesis of (S)—tert-butyl 3—amin0-3—(6—(diflu0r0meth0xy)pyridin
yl)pr0pan0ate (S—029): To a stirred solution of nd 5 (0.80 g, crude mixture) in
EtOAc (5 mL) and AcOH (0.5 mL), 20% Pd(OH)2 (50 mg) was added under N2 atmosphere.
The reaction mixture was stirred under H2 atmosphere (40 psi) at RT for 2 h. After
consumption of the starting material (monitored by TLC), the reaction mixture was filtered
through a pad of CELITE®. Filtrate was concentrated under reduced re to afford crude
compound which was purified by column chromatography (2% MeOH/DCM) to furnish S—
029 (0.3 g, 63%) as yellow syrup.
TLC: 5% CM (Rf: 0.3)
1H NMR (400 MHZ, : 6 8.17 (d, J= 2.8 Hz, 1H), 7.78 (dd, J= 2.4, 6.4 Hz, 1H), 7.44
(t, 73.2 Hz, 1H), 6.88 (d, J: 8.4 Hz, 1H), .40 (m, 1H), 2.65—2.56 (m, 2H), 1.42 (s, 9H)
LC-MS: m/z = 274 [M+H]+ at RT 2.76 (99.8% purity)
(S, E)—tert—Butyl 3-(6—(tert-but0xy) pyridin—3—yl)—3-((2, 2—
dimethoxyethylidene)amino)pr0pan0ate (7): To a stirred on of dimethoxy
acetaldehyde (0.44 mL, 2.50 mmol, 1.20 equiv., 60% in water) in DCM (10 mL), cooled to
0°C, anhydrous MgSO4 (10 g) was added followed by S-029 (600 mg, 2.08 mmol, 1.0 equiv.)
in DCM (5 mL). The reaction was continued at RT for 2h and filtered through a pad of
CELITE®, the filtrate was concentrated under reduced pressure to afford nd 7 (650
mg, crude) as a yellow liquid which was used in the next step without any purification.
TLC: 5% MeOH/DCM (Rf: 0.5)
(S)-tert-butyl 3-(6-(diflu0romethoxy)pyridinyl)((2, 2—dimethoxyethyl)
amino) oate (8): To a stirred solution of compound 7 (0.65 g, crude, 1.0 equiv.) in
MeOH (7 mL), cooled to 0°C, NaBH(CN)3 (0.13 g, 2.09 mmol, 1.20 equiv.) was added and
the reaction mixture was stirred at RT for 2 h. After consumption of the starting material (by
TLC), MeOH was removed under reduced pressure to give the crude residue which was
diluted with water (10 mL) and extracted with EtOAc (2 x10 ml). The combined organic
extracts were dried over anhydrous Na2SO4, filtered and concentrated under d pressure
to give the crude material which was purified by column tography (2% MeOH/DCM)
to afford nd 8 (0.52 g, 79%) as a thick syrup.
TLC: 5% MeOH/DCM (Rf: 0.7)
1H NMR (400 MHz, : 8 8.13 (d, J= 2.0 Hz, 1H), 7.75 (dd, J: 2.4, 6.0 Hz, 1H), 7.44
(t, J= 73.2 Hz, 1H), 6.87 (d, J: 8.4 Hz, 1H), 4.43-4.37 (m, 2H), .02 (m, 1H), 3.60-
3.54 (m, 2H), 3.35 (s, 3H) 3.31 (s, 3H), 2.66-2.57 (m, 2H), 1.39 (s, 9H)
LC-MS: m/z = 377 [M+H]+ at RT 2.96 (92.3% purity)
(S)-tert-butyl 3-(6-(diflu0r0methoxy) pyridin-S-yl)(1-(2, 2-dimeth0xyethyl)
(3-(5, 6, 7, 8-tetrahydro-1, 8-naphthyridinyl)propyl)ureido)pr0panoate (10) : To a
stirred solution of compound 8 (375 mg, 0.99 mmol, 1.0 equiv.) in dry DCM (5 mL), cooled
to 0°C, triphosgene (1.50 mL, 2.99 mmol, 3.00 equiv., 20% in PhMe) followed by Et3N (0.30
mL, 2.09 mmol, 2.10 equiv) were added. The reaction mixture was slowly brought to RT and
stirred for 2 h. After completion of the starting material, volatiles were evaporated to afford
the crude compound 9, which was used directly in the next step without purification. A
solution of nd 9 in DCE (2 mL) was added to a solution of compound 6b (400 mg,
1.32 mmol, 1.32 ) in DCM (5 mL), Et3N (0.55 mL, 3.98 mmol, 4.00 equiv) at 0°C and
stirred at RT for 4 h. After consumption of the starting material ored by TLC), the
reaction mixture was concentrated under reduced pressure to give the crude residue which
was purified by column chromatography (2% MeOH/DCM) to afford compound 10 (0.40 g,
67%) as a thick syrup.
TLC: 5% MeOH/DCM (Rf: 0.2)
1H NMR (400 MHz, CDC13): 8 8.13 (d, J= 2.8 Hz, 1H), 7.79 (dd, J= 2.4, 6.4 Hz, 1H), 7.62
(tt, J= 72.8 Hz, 1H), 7.12 (d, J= 6.4 Hz,1H), 6.86 (d, J= 8.4 Hz, 1H), 6.36 (d, J: 3.6 Hz,
1H), 6.22 (t, J= 4.8 Hz, 1H), 5.75 (t, J= 7.6 Hz, 1H), 4.26 (t, J: 5.2 Hz, 1H), 3.45—3.38 (m,
8H), 3.27—3.13 (m, 3H), 2.99—2.93 (m, 2H), 2.71-2.59 (m, 5H), 1.93—1.83 (m, 5H), 1.39 (s,
LC-MS: m/z = 594 + at RT 3.42 (88.1% purity)
(S)-tert-Butyl 3-(6-(difluorometh0xy) nyl)(2-0x0(3-(5, 6, 7, 8-
tetrahydro-l, 8~naphthyridinyl)pr0pyl)-2, 3-dihydr0-1H-imidazolyl)pr0pan0ate
(11): To a stirred solution of compound 10 (0.20 g, 0.34 mmol, 1.0 equiv.) in THF (4 mL), at
—10 °C, 1 M sulfuric acid (0.8 mL) was added. The reaction was slowly warmed to RT and
stirred for 10 h. After ption of the starting material (monitored by LCMS), THF was
removed and the crude residue was lized with sodium hydroxide (50 wt %) till pH ~7.
The aqueous layer was extracted with 5% MeOH/DCM (3 x 20 mL) and the combined
organic ts were dried over anhydrous Na2SO4, filtered and concentrated under reduced
pressure to furnish compound 11 (0.22 g, crude) as a syrup.
TLC: 10% CM (Rf: 0.5)
LC—MS: m/z = 530 [Mi—H]+ at RT 4.06 (72.8% )
(S)-tert-Butyl 3-(6-(diflu0r0meth0xy) pyridinyl)(2-0x0(3-(5, 6, 7, 8-
tetrahydro-l, 8-naphthyridinyl)propyl) imidazolidiny1)pr0pan0ate (12): To a
stirred on of compound 11 (0.45 g, crude, 1.0 equiv.) in EtOH (8 mL), 20% Pd/C (200
mg) was added under N2 atmosphere. The on mixture was stirred under H2 atmosphere
(40 psi) at RT for 36 h. After consumption of the starting material the reaction mixture was
filtered through a pad of CELITE®, and the filtrate was concentrated under reduced pressure
to afford crude compound 12, which was purified by chiral ative HPLC to afford
compound 12 (450 mg, crude) as an off-white solid.
TLC: 10% MeOH/DCM (Rf: 0.5)
LC-MS: m/z = 532.6 [M+H]+ at RT 3.99 (80.1% purity)
(S)(6-(difluoromethoxy)pyridinyl)—3-(2—0x0(3-(5, 6, 7, 8-tetrahydr0-1, 8-
naphthyridinyl)propyl) imidazolidinyl)propan0ic acid (Compound A1); To a
stirred solution of compound 12 (0.40 g, crude, 1.0 equiv.) in DCM (2 mL), cooled to —10°C,
TFA (0.5 mL) was added under N2 atmosphere. The reaction was slowly brought to RT and
stirred for 2h; after consumption of the starting material, volatiles were evaporated to afford
crude (400 mg) compound, which was purified by chiral preparative HPLC to afford
compound A1 as an off—white solid.
TLC: 10% MeOH/DCM (Rf: 0.3)
1H NMR (400 MHz, CD30D): 6 8.20 (d, J: 2.4 Hz, 1H), 7.85 (dd, J= 2.4, 6.4 Hz, 1H), 7.53
(t, ,J= 2.4 Hz, 1H), 7.50 (d, J: 7.2 Hz, 1H), 6.98 (d, J: 8.4 Hz, 1H), 6.57 (d, J= 7.2 Hz,
1H), 5.51 (dd, J= 3.6, 8.0 Hz, 1H), 3.68—3.61 (m, 1H), 3.52—3.46 (m, 3H), 3.38 (m, 1H), 3.24-
3.17 (m, 1H), 3.07—2.98 (m, 2H), .62 (m, 6H), 2.09—1.81 (m, 4H).
LC-MS: m/z = 476 [M+H]+ at RT 2.78 (97.9% purity)
HPLC purity: 96.4%; Chiral : 99%
The compounds of the present invention described in Examples 2—7 in which Z is -
CHzCHzCHz— were synthesized using the general reaction scheme shown in Scheme 2.
yl (2-oxo(5,6,7,8-tetrahydro-1,8—naphthyridinyl)hexyl)phosphonate was added
to the fluorinated nitrogen heterocycle (Q) aldehyde to form the hept-1—enone. The hept—
1-en—3-one was reduced to the corresponding heptenol using lithium aluminum hydride
or sodium borohydride. The hepten-3ol was then reacted with proprionic acid in 1,1,1-
triethoxyethane and the resulting crude rearrangement product was reduced with hydrogen
and palladium on carbon catalyst to the corresponding olefin reduction product which was
then reacted with aqueous base to form the final nonanoic acid compounds.
Example 2. Synthesis of 9—(5,6,7,8-tetrahydro-1,8-naphthyridin-2—yl)(2-
oromethyl)pyrimidinyl)nonanoic acid (Compound A2)
(E)-7—(5,6,7,8-tetrahydro-1,8-naphthyridin-Z-yl)-1—(2—(trifluoromethyl)pyrimidin-
-yl)hept—1—en-3—one
o o
H n
N N
\ P\—OMe
I OMe O
/ H
__”—_,t-B OK N /
+ / N
THF IN\
\NJ\CF31 /
OHCfij:
N CF3
Under nitrogen, to dimethyl (2-oxo(5,6,7,8-tetrahydro-1,8-naphthyridin
yl)hexyl)phosphonate (3.40 g, 10.0 mmol, 1.00 equiv; n, P. J. et al., J. Med. Chem.
2004, 47:4829—4837) in THF (10 mL) at 23 °C was added fluoromethyl)pyrimidine—5-
carbaldehyde (1.76 g, 10.0 mmol, 1.00 equiv) and t—BuOK (1.01 g, 9.00 mmol, 0.900 equiv).
After stirring for 10 min at 23 °C, the reaction mixture was ly loaded on silica gel and
purified by column chromatography on silica gel g with CHzClz/MeOH to afford 2.10 g
of the title compound (54% yield).
1H NMR (300 MHz, CDCl3, 23 °C, 5): 9.03 (s, 2H), 7.50 (d, J= 16.2 Hz, 1H), 7.07 (d, J:
7.2 Hz, 1H), 6.93 (d, J= 16.2 Hz, 1H), 6.35 (d, J: 7.2 Hz, 1H), 5.17 (br s, 1H), 3.42—3.37
(m, 2H), .64 (m, 4H), 2.62—2.55 (m, 2H), 1.95—1.85 (m, 2H), 1.77—1.66 (m, 4H). 19P
NMR (282 MHz, CDCl3, 23 °C, 5): —70.3 (s, 3F).
(E)-7—(5,6,7,8—tetrahydro-1,8-naphthyridinyl)(2-(trifluoromethyl)pyrimidin-
-yl)hept—1—en—3—ol
O OH
H H
N N / LIA1H4' N
\ / j: 1N\ /
I N
THF \NJ\CF31 / \ /
N 01:3
Under nitrogen, to (E)(5 ,6,7,8—tetrahydro— 1 ,8—naphthyridinyl)— 1 -(2-
(trifluoromethyl)pyrimidinyl)hept-1—en-3—one (1.20 g, 3.07 mmol, 1.00 equiv) in THF (15
mL) at —78 °C was added LiAlH4 (1.0 M in THF, 3.07 mL, 307 mmol, 1.00 equiv). After
stirring for 10 min at —78 °C, H20 (116 uL), 15% NaOH aq (116 uL) and H20 (348 uL) were
added sequentially to the reaction mixture. The reaction e was warmed to 23 °C and
filtered through a pad of CELITE®. The filtrate was concentrated in vacuo and the residue
was purified by column chromatography on silica gel eluting with CH2Clz/MCOH to afford
560 mg of the title nd (46% yield).
1H NMR (300 MHz, CDC13, 23 °C, 5): 8.86 (s, 2H), 7.06 (d, J: 7.2 Hz, 1H), 6.66 (d, J:
16.2 Hz, 1H), 6.53 (dd, J= 16.2 Hz, 4.5 Hz, 1H), 6.34 (d, J: 7.2 Hz, 1H), 4.81 (br s, 1H),
4.50—4.40 (m, 1H), 3.42—3.37 (m, 2H), 2.70—2.50 (m, 4H), 1.96—1.40 (m, 8H). 19P NMR (282
MHz, CDC13, 23 °C, 5): —70.1 (s, 3F).
9—(5,6,7,8-tetrahydro—1,8—naphthyridin-Z-yl)(2-(trifluoromethyl)pyrimidin
yl)n0nanoic acid (Compound A2)
1. ElCOZH O
OH MeC(OEt)3
ZI 2. H2, Pd/C, HO
\ H
/ \ z TFA, MeOH
l N N
\NJ\CF3l ——-——-—-—> \ / N
3. NaOH, H20 l
/ \
MeOH N CF3
Under nitrogen, to (5,6,7,8—tetrahydro—1,8-naphthyridin—2-yl)-l-(2-
(trifluoromethyl)pyrimidinyl)hept—l—en—3—ol (560 mg, 1.43 mmol, 1.00 equiv) in
MeC(OEt)3 (14 mL) at 23 °C was added EtCOzH (107 uL, 1.43 mmol, 1.00 equiv). After
ng for 2 hr at 140 0C, the reaction mixture was ly loaded on silica gel and purified
by column chromatography on silica gel eluting with hexanes/EtOAc to afford a crude
rearrangement product, which was used in the next step without further purification.
Under air, to the above obtained e in FA (10 mL—l mL) at 23 °C was
added 10% Pd/C (103 mg, 0.0969 mmol, 6.78 mol%) and H2 was introduced with a balloon.
After stirring for 1 hr at 23 °C, the reaction mixture was filtered h a pad of CELITE®.
The filtrate was concentrated in vacuo to afford a crude olefin reduction product, which was
used in the next step without further purification.
Under air, to the above obtained residue in MeOH (10 mL) at 23 °C was added 15%
NaOH aq (2.7 mL). After stirring for 20 min at 60 °C, the reaction e was neutralized
with 3N HCl and concentrated in vacuo to remove MeOH. The residual aqueous solution
was ted with EtOAc (3 >< 10 mL) and the combined organic phases were washed with
NaHC03 aq (2 X 5 mL) and dried (MgSO4). The filtrate was trated in vacuo and the
residue was purified by column chromatography on silica gel eluting with CHzClz/MeOH to
afford 280 mg of the title compound (45% yield over 3 steps).
1H NMR (300 MHz, CDCl3, 23 °C, 8): 8.79 (s, 2H), 7.24 (d, J: 7.2 Hz, 1H), 6.25 (d, J= 7.2
Hz, 1H), 3.48—3.40 (m, 2H), 3.38—3.32 (m, 1H), 2.75—2.52 (m, 4H), 1.95—1.80 (m, 4H),
.58 (m, 4H), 1.40—1.18 (m, 6H). 19P NMR (282 MHz, CDCl3, 23 °C, 8): —70.1 (s, 3F).
Example 3. Synthesis of 3-(6-(difluoromethoxy)pyridin—3-yl)-9—(5,6,7,8-tetrahydro-l,8—
naphthyridin-2—yl)nonanoic acid (Compound A3)
6-(difluoromethoxy)nicotinaldehyde
an t-BuLi; DMF
/ THF CHOU/
N OCHF2 N OCHF2
Under nitrogen, to 5—bromo(difluoromethoxy)pyridine (448 mg, 2.00 mmol, 1.00
equiv; Ando, M. et al., Org. Lett. 2006, —3 808) in THF (10 mL) at —78 °C was added
t-BuLi (1.7 M in pentane, 2.35 mL, 4.00 mmol, 2.00 equiv) dropwise over 5 min. After
stirring for 20 min at —78 °C, DMF (0.54 mL, 7.0 mmol, 3.5 equiv) was added to the reaction
mixture. After stirring for 20 min at —78 °C, 1N HCl aq (10 mL) was added to the reaction
mixture and the reaction mixture was warmed to 23 °C. The phases were separated and the
aqueous phase was extracted with EtOAc (3 X 5 mL). The combined organic phases were
washed with brine (10 mL) and dried (MgSO4). The filtrate was concentrated in vacuo and
the residue was purified by column chromatography on silica gel eluting with hexanes/EtOAc
to afford 105 mg of the title compound (30% yield).
1H NMR (300 MHz, CDCl3, 23 °C, 8): 10.05 (s, 1H), 8.69 (d, J= 2.1 Hz, 1H), 8.24 (dd, J=
8.4 Hz, 2.4 Hz, 1H), 7.56 (t, J= 72.3 Hz, 1H), 7.04 (d, J: 8.4 Hz, 1H). ”P NMR (282 MHz,
CDC13, 23 °C, 8): ~89.8 (d, J: 72.3 Hz, 2F).
(E)—1—(6—(difluoromethoxy)pyridin—3-yl)—7-(5,6,7,8—tetrahydro-1,8-naphthyridin-
2-yl)hept—1-en-3—one
O O
H [I
N N
\ R—OMe
l OMe O
_______.l LCI,DBU. N N\ /
+ /
OHC N OCHF2
N OCHF2
Under nitrogen, to dimethyl (2-oxo—6—(5,6,7,8—tetrahydro—1,8-naphthyridin—2-
yl)hexyl)phosphonate (1.57 g, 4.62 mmol, 1.00 equiv) in MeCN (11 mL) at 23 °C was added
6—(difluoromethoxy)nicotinaldehyde (800 mg, 4.62 mmol, 1.00 equiv), LiCl (196 mg, 4.62
mmol, 1.00 equiv) and DBU (0.725 mL, 4.85 mmol, 1.05 equiv). After stirring for 1 hr at 50
°C, the reaction mixture was cooled to 23 °C and was filtered through a pad of CELITE®.
The filtrate was concentrated in vacuo and the residue was purified by column
chromatography on silica gel eluting with CH2C12/MeOH to afford 1.27 g of the title
compound (71% yield).
1H NMR (300 MHz, CDC13, 23 °C, 8): 8.32 (d, J: 2.4 Hz, 1H), 7.92 (dd, J: 8.4 Hz, 2.4 Hz,
1H), 7.49 (t, J: 72.3 Hz, 1H), 7.47 (d, J: 16.2 Hz, 1H), 7.06 (d, J: 7.2 Hz, 1H), 6.93 (d, J:
8.7 Hz, 1H), 6.70 (d, J: 16.2 Hz, 1H), 6.35 (d, J= 7.2 Hz, 1H), 4.89 (br s, 1H), 3.42—3.36
(m, 2H), 2.76—2.64 (m, 4H), .56 (m, 2H), 1.94—1.85 (m, 2H), .66 (m, 4H). 19F
NMR (282 MHZ, CDC13, 23 °C, 8): —89.2 (d, J= 72.3 Hz, 2F).
(E)(6-(difluoromethoxy)pyridin—3-yl)—7—(5,6,7,8—tetrahydro-1,8—naphthyridin—
2-yl)hept—1-enol
O OH
LIAIH4.
N N\ / N N /
/ /
I l -——————-—-—————>
/ \ THF l /\ l
N OCHFz N oczHF2
Under en, to (E)—1-(6-(difluoromethoxy)pyridin—3-yl)—7—(5,6,7,8-tetrahydro-1 ,8—
naphthyridinyl)hepten—3—one (1.27 g, 3.28 mmol, 1.00 equiv) in THF (33 mL) at 0 °C
was added LiAlH4 (1.0 M in THF, 3.28 mL, 3.28 mmol, 1.00 equiv). After stirring for 10
min at 0 °C, H20 (124 uL), 15% NaOH aq (124 uL) and H20 (372 ML) were added
sequentially to the reaction e. The reaction mixture was warmed to 23 °C and d
through a pad of CELITE®. The filtrate was concentrated in vacuo and the residue was
purified by column chromatography on silica gel eluting with CH2C12/MeOH to afford 1.05 g
of the title compound (82% yield).
2014/015372
1H NMR (300 MHz, CDCl3, 23 °C, 8): 8.22 (d, J: 2.4 Hz, 1H), 7.84 (dd, J: 8.4 Hz, 2.4 Hz,
1H), 7.49 (t, J= 72.3 Hz, 1H), 7.05 (d, J= 7.2 Hz, 1H), 6.88 (d, J= 8.7 Hz, 1H), 6.66 (d, J:
16.2 Hz, 1H), 6.55 (dd, J: 16.2 Hz, 4.5 Hz, 1H), 6.33 (d, J: 7.2 Hz, 1H), 4.84 (br s, 1H),
4.52—4.43 (m, 1H), 3.40—3.37 (m, 2H), 2.72—2.51 (m, 4H), 1.95—1.40 (m, 8H). 19F NMR (282
MHz, CDClg, 23 °C, 8): —89.0 (d, J= 72.5 Hz, 2F).
3-(6-(difluoromethoxy)pyridin-3—yl)(5,6,7,8—tetrahydro-1,8-naphthyridin
yl)nonanoic acid (Compound A3)
1. EtCOZH
OH MeC(OEt)3
232 2. H2, Pd/C,
/z \
\ TFA, MeOH
I I ——-———>
N OCHF2 3. NaOH, H20
MeOH OCHF2
Under nitrogen, to (E)—1-(6-(difluoromethoxy)pyridin-3 -yl)(5,6,7,8-tetrahydro~1,8-
naphthyridin—2—yl)hept-1~enol (1.05 g, 2.70 mmol, 1.00 equiv) in MeC(OEt)3 (27 mL) at
23 °C was added EtCOzH (201 ML, 2.70 mmol, 1.00 equiv). After stirring for 2 hr at 140 °C,
the reaction mixture was directly loaded on silica gel and purified by column tography
on silica gel eluting with hexanes/EtOAc to afford a crude rearrangement product, which was
used in the next step without further purification.
Under air, to the above obtained residue in MeOH—TFA (10 mL—l mL) at 23 °C was
added 10% Pd/C (176 mg, 0.165 mmol, 6.11 mol%) and H2 was introduced with a n.
After stirring for 1 hr at 23 °C, the reaction mixture was filtered through a pad of CELITE®.
The filtrate was concentrated in vacuo to afford a crude olefin reduction product, which was
used in the next step t further purification.
Under air, to the above obtained residue in MeOH (10 mL) at 23 °C was added 15%
NaOH aq (4.4 mL). After stirring for 20 min at 60 °C, the reaction mixture was neutralized
with 3N HCl and trated in vacuo to remove MeOH. The residual aqueous solution
was extracted with EtOAc (3 X 10 mL) and the combined organic phases were washed with
NaHC03 aq (2 X 5 mL) and dried (MgSO4). The filtrate was trated in vacuo and the
residue was purified by column chromatography on silica gel eluting with CH2C12/MeOH to
afford 400 mg of the title compound (34% yield over 3 steps).
1H NMR (300 MHz, CDClg, 23 °C, 8): 8.06 (d, J= 2.4 Hz, 1H), 7.66 (dd, J= 8.4 Hz, 2.4 Hz,
1H), 7.43 (t, J= 72.3 Hz, 1H), 7.20 (d, J: 8.7 Hz, 1H), 6.84 (d, J: 7.2 Hz, 1H), 6.25 (d, J:
7.2 Hz, 1H), 3.46—3.40 (m, 2H), 3.38—3.28 (m, 1H), 2.79—2.40 (m, 4H), .80 (m, 4H),
1.75—1.62 (m, 4H), 1.40—1.20 (m, 6H). 19F NMR (282 MHz, CDCl3, 23 0C, 8): —88.3 (d, J=
72.5 Hz, 2F).
Example 4. Synthesis of 3-(6-fluoroquinolinyl)(5,6,7,8—tetrahydro-1,8-naphthyridin—2-
anoic acid (Compound A4)
6-fluoroquinoline—3-carbaldehyde
EtsN,HCOZH
OHC F Pd(PPh3)4 OHC F
/| /|
C! \N \N
Under nitrogen, to 2-chlorofluoroquinolinecarbaldehyde (2.03 g, 9.68 mmol,
1.00 equiv) in DMF (10 mL) at 23 °C was added triethylamine (16.2 mL, 116 mmol, 12.0
equiV), Pd(PPh3)4 (559 mg, 0.484 mmol, 5.00 mol%), and formic aid (1.29 mL, 34.2 mmol,
.40 equiv). After stirring for 1 hr at 100 °C, the reaction mixture was cooled to 23 °C and
water (40 mL) and EtOAc (30 mL) was added. The phases were separated and the aqueous
phase was extracted with EtOAc (3 X 30 mL). The ed organic phases were washed
with brine (50 mL) and dried (MgSO4). The filtrate was concentrated in vacuo and the
residue was purified by column chromatography on silica gel eluting with hexanes/EtOAc to
afford 734 mg of the title compound (43% .
1H NMR (300 MHZ, CDCl3, 23 °C, 5): 10.27 (s, 1H), 9.34 (d, J= 2.1 Hz, 1H), 8.60 (d, J=
1.8 Hz, 1H), 8.21 (dd, J= 9.0 Hz, 4.8 Hz, 1H), 7.70—7.60 (m, 2H). 19F NMR (282 MHz,
CDCl3, 23 °C, 5): —110.8 (m, 1F).
(E)—1—(6-fluoroquinolinyl)—7-(5,6,7,8-tetrahydro-1,8-naphthyridin-Z-yl)hept—1-
enone
H .0.
N N
\ P\-OMe
l OMe O
/ H
LiCI,DBU N
+ [N\ / F
MeCN I
/ \
OHC F N
Under nitrogen, to yl (2-oxo(5,6,7,8-tetrahydro-1,8—naphthyridin
yl)phosphonate (900 mg, 2.64 mmol, 1.10 equiv) in MeCN (22 mL) at 23 °C was
added 6-fluoroquinolinecarba1dehyde (420 mg, 2.40 mmol, 1.00 , LiCl (101 mg,
2.40 mmol, 1.00 equiv) and DBU (0.377 mL, 2.52 mmol, 1.05 equiv). After stirring for 1 hr
at 75 °C, the reaction mixture was cooled to 23 °C and was filtered through a pad of
CELITE®. The filtrate was concentrated in vacuo and the residue was purified by column
chromatography on silica gel eluting with CHZClz/MeOH to afford 900 mg of the title
compound (96% yield).
1H NMR (300 MHZ, CDC13, 23 °C, 8): 9.06 (d, J= 2.4 Hz, 1H), 8.21 (d, J: 2.1 Hz, 1H), 8.11
(dd, J= 10.6 Hz, 5.7 Hz, 1H), 7.66 (d, J: 16.2 Hz, 1H), 7.58—7.43 (m, 2H), 7.06 (d, J: 7.2
Hz, 1H), 6.96 (d, J= 16.2 Hz, 1H), 6.37 (d, J= 7.2 Hz, 1H), 4.76 (br s, 1H), 3.43~3.35 (m,
2H), .65 (m, 4H), 2.63—2.56 (m, 2H), 1.94—1.85 (m, 2H), 1.82—1.66 (m, 4H). 19P NMR
(282 MHz, CDC13, 23 °C, 8): ~111.9 (m, 1F).
(6-flu0r0quinolinyl)(5,6,7,8-tetrahydr0-1,8-naphthyridin-Z-yl)hept—1-
enol
O OH
H H
N iN\ / F NaBH4 N F
/ N\ /
\N MGOH l I
/ \N
Under air, to (E)—1-(6—fluoroquinolin—3—yl)(5,6,7,8-tetrahydro—1,8—naphthyridin—2—
yl)hept—1—en-3—one (490 mg, 1.26 mmol, 1.00 equiv) in MeOH (29 mL) at 0 °C was added
NaBH4 (71.5 mg, 1.89 mmol, 1.5 equiv). After stirring for 1 hr at 0 °C, 1N HCl aq (10 mL)
was added to the reaction e and concentrated in vacuo to remove MeOH. The residue
was neutralized with NaHCO3 aq and EtOAc (10 mL) was added. The phases were separated
and the aqueous phase was extracted with EtOAc (3 X 20 mL). The combined organic phases
were washed with brine (30 mL) and dried (MgSO4). The filtrate was concentrated in vacuo
and the residue was purified by column chromatography on silica gel eluting with
CH2Clg/MCOH to afford 490 mg of the title compound (99% yield).
1H NMR (300 MHZ, CDC13, 23 °C, 8): 8.95 (s, 1H), 8.06 (dd, J= 10.6 Hz, 5.7 Hz, 1H), 7.99
(s, 1H), 7.50—7.40 (m, 2H), 7.06 (d, J2 7.2 Hz, 1H), 6.75 (d, J: 16.2 Hz, 1H), 6.49 (dd, J:
16.2 Hz, 4.5 Hz, 1H), 6.34 (d, J2 7.2 Hz, 1H), 4.94 (br s, 1H), 4.47—4.39 (m, 1H), 3.42—3.38
(m, 2H), 2.70—2.47 (m, 4H), 1.96—1.45 (m, 8H). 19P NMR (282 MHz, CDC13, 23 °C, 8): —
111.8 (m, 1F).
3-(6-flu0roquinolinyl)—9—(5,6,7,8-tetrahydro-1,8-naphthyridin—2—yl)n0nanoic
acid (Compound A4)
1. EtCOZH
OH MeC(OEt)3
2:: 2. H2, Pd/C,
/ \ TFA, MeOH
l l ————-—->
N 3. NaOH, H20
MeOH
Under nitrogen, to (E)(6—fluoroquinolinyl)—7—(5,6,7,8—tetrahydro—1 ,8-
naphthyridin-2—yl)hept—1—en—3—ol (489 mg, 1.25 mmol, 1.00 equiv) in MeC(OEt)3 (12 mL) at
23 °C was added EtC02H (93.3 uL, 1.25 mmol, 1.00 equiv). After stirring for 2 hr at 140 °C,
the reaction e was directly loaded on silica gel and purified by column chromatography
on silica gel eluting with hexanes/EtOAc to afford a crude ngement t, which was
used in the next step without further purification.
Under air, to the above obtained residue in MeOH—TFA (10 mL—1 mL) at 23 °C was
added 10% Pd/C (128 mg, 0.121 mmol, 9.68 mol%) and H2 was introduced with a balloon.
After stirring for 1 hr at 23 °C, the reaction mixture was filtered through a pad of CELITE®.
The filtrate was concentrated in vacuo to afford a crude olefin reduction product, which was
used in the next step without further purification.
Under air, to the above obtained e in MeOH (10 mL) at 23 °C was added 15%
NaOH aq (3.0 mL). After stirring for 20 min at 60 °C, the reaction mixture was neutralized
with 3N HCl and concentrated in vacuo to remove MeOH. The residual aqueous solution
was extracted with EtOAc (3 X 10 mL) and the combined organic phases were washed with
NaHC03 aq (2 X 5‘mL) and dried (MgSO4). The e was trated in vacuo and the
residue was purified by column chromatography on silica gel eluting with /MeOH to
afford 500 mg of the title compound (92% yield over 3 steps).
1H NMR (300 MHz, CD301), 23 °C, 8): 8.78 (s,‘1H), 8.11 (s, 1H), 8.00—7.93 (m, 1H), 7.52—
7.42 (m, 2H), 7.31 (d, J= 7.2 Hz, 1H), 6.35 (d, J= 7.2 Hz, 1H), 3.38—3.20 (m, 3H), 2.77—
2.42 (m, 4H), 1.90—1.20 (m, 14H). 19F NMR (282 MHz, , 23 °C, 8): —110.9 (m, 1F).
Example 5. Synthesis of 3-(7-fiuoroquinolinyl)(5,6,7,8-tetrahydro-l,8-naphthyridin
yl)nonanoic acid (Compound A5)
(E)(7-flu0roquinolinyl)(5,6,7,8-tetrahydro-1,8-naphthyridinyl)hept—1-
en0ne
H 9
N N
\ P\—OMe
I OMe O
/ H
BU N
+ |N\ /
MeCN |
/ \
OHC N F
N F
Under nitrogen, to dimethyl (2—oxo-6—(5,6,7,8-tetrahydro-1,8—naphthyridin
yl)hexyl)phosphonate (749 mg, 2.20 mmol, 1.10 equiv) in MeCN (22 mL) at 23 °C was
added 7-fiuoroquinolinecarbaldehyde (350 mg, 2.00 mmol, 1.00 equiv; Sato, 1. et al.,
Synthesis 2004, 9: 1419—1428), LiCl (84.8 mg, 2.00 mmol, 1.00 equiv) and DBU (0.314 mL,
2.10 mmol, 1.05 equiv). After stirring for 1 hr at 75 °C, the reaction mixture was cooled to
23 °C and was filtered through a pad of CELITE®. The filtrate was concentrated in vacuo
and the residue was purified by column chromatography on silica gel eluting with
CH2C12/MCOH to afford 570 mg of the title compound (73% yield).
1H NMR (300 MHz, CDC13, 23 °C, 8): 9.10 (d, J= 2.4 Hz, 1H), 8.28 (d, J= 2.1 Hz, 1H), 7.87
(dd, J: 9.0 Hz, 6.0 Hz, 1H), 7.74 (dd, J= 9.9 Hz, 2.4 Hz, 1H), 7.69 (d, J: 16.2 Hz, 1H),
7.42—7.33 (m, 1H), 7.11 (d, J? 7.2 Hz, 1H), 6.94 (d, J: 16.2 Hz, 1H), 6.37 (d, J: 7.2 Hz,
1H), 5.41 (br s, 1H), 3.43—3.37 (m, 2H), 2.78—2.58 (m, 6H), 1.93—1.85 (m, 2H), 1.81—1.69
(m, 4H). ”P NMR (282 MHz, CDC13, 23 °C, 8): —107.0 (m, 1F).
(E)(7-fluoroquin01in-3—yl)—7—(5,6,7,8—tetrahydro-l,8-naphthyridin-Z-yl)hept
enol
H OH
N N\ / NaBH4 N
/ N\ /
| 1 |
/ MeOH l
\N F / \N F
Under air, to (E)-1—(7-fluoroquinolinyl)(5,6,7,8—tetrahydro-1,8-naphthyridin
t—1-en—3—one (300 mg, 0.770 mmol, 1.00 equiv) in MeOH (8 mL) at 0 °C was added
NaBH4 (87.4 mg, 2.31 mmol, 3.00 equiv). After stirring for 30 min at 0 °C, 1N HCl aq (10
mL) was added to the reaction mixture and concentrated in vacuo to remove MeOH. The
residue was neutralized with NaHCO3 aq and EtOAc (10 mL) was added. The phases were
separated and the aqueous phase was ted with EtOAc (3 X 20 mL). The combined
organic phases were washed with brine (30 mL) and dried (MgSO4). The filtrate was
concentrated in vacuo and the residue was purified by column chromatography on silica gel
eluting with CHzClz/MeOH to afford 210 mg of the title compound (70% yield).
1H NMR (300 MHz, CDCl3, 23 °C, 5): 8.98 (s, 1H), 8.07 (s, 1H), 7.81 (dd, J= 9.0 Hz, 6.0
Hz, 1H), 7.78 (dd, J: 9.9 Hz, 2.4 Hz, 1H), 7.63 (br s, 1H), 7.39—7.28 (m, 1H), 6.78 (d, J:
16.2 Hz, 1H), 6.47 (dd, J: 16.2 Hz, 4.5 Hz, 1H), 6.36 (d, J: 7.2 Hz, 1H), 4.48—4.41 (m,
1H), 3.48—3.41 (m, 2H), 2.79~2.67 (m, 4H), 1.97—1.48 (m, 8H). 19P NMR (282 MHz, CDC13,
23 °C, 5): —109.9 (m, 1F).
uoroquin01inyl)—9-(5,6,7,8-tetrahydro-1,8—naphthyridin-Z-yl)nonanoic
acid (Compound A5)
1.EtC02H
OH MeC(OEt)3
ZI 2. H2, Pd/C,
N /
/ / OH
| l —————-———-—————>
/ \N F 3. NaOH, H20
MeOH
Under nitrogen, to (ID(7—fluoroquinolin—3—yl)—7—(5,6,7,8-tetrahydro—1 ,8—
naphthyridinyl)heptenol (730 mg, 1.71 mmol, 1.00 equiv) in t)3 (17 mL) at
23 °C was added EtCOzH (128 uL, 1.71 mmol, 1.00 equiv). After stirring for 2 hr at 140 0C,
the reaction mixture was directly loaded on silica gel and purified by column chromatography
on silica gel eluting with hexanes/EtOAc to afford a crude rearrangement t, which was
used in the next step without further purification.
Under air, to the above obtained residue in MeOH—TFA (10 mL—1 mL) at 23 °C was
added 10% Pd/C (125 mg, 0.117 mmol, 6.84 mol%) and H2 was introduced with a balloon.
After stirring for 1 hr at 23 °C, the reaction e was filtered through a pad of CELITE®.
The filtrate was concentrated in vacuo to afford a crude olefin ion product, which was
used in the next step without further purification.
Under air, to the above ed residue in MeOH (10 mL) at 23 °C was added 15%
NaOH aq (3.0 mL). After stirring for 20 min at 60 °C, the reaction mixture was neutralized
with 3N HCl and concentrated in vacuo to remove MeOH. The residual aqueous solution
was extracted with EtOAc (3 X 10 mL) and the combined c phases were washed with
NaHC03 aq (2 X 5 mL) and dried (MgSO4). The e was concentrated in vacuo and the
e was purified by column chromatography on silica gel eluting with CHzClz/MeOH to
afford 480 mg of the title compound (64% yield over 3 steps).
IHNMR (300 MHz, CD3OD, 23 °C, 8): 8.79 (s, 1H), 8.21 (s, 1H), 8.00—7.91 (m, 1H), 7.62—
7.57 (m, 1H), 7.48—7.38 (m, 2H), 6.47 (d, J= 7.2 Hz, 1H), 3.48—3.30 (m, 3H), 2.80—2.52 (m,
4H), 1.90—1.20 (m, 14H). I9F NMR (282 MHz, CD3OD, 23 °C, 8): —111.9 (m, 1F).
Example 6. Synthesis of 3-(6,7-difluoroquinolin-3—yl)(5,6,7,8—tetrahydro—1,8—
naphthyridin—2-yl)nonanoic acid (Compound A6)
6,7-difluoroquinolinecarbaldehyde
EtsN, HCOZH
OHC F
/ Pd(PPh3)4
1 OHCWF
CI \N DMF
F \N F
Under en, to 2—chloro-6,7-difluoroquinoline-3—carbaldehyde (1.44 g, 6.33 mmol,
1.00 equiv) in DMF (6.3 mL) at 23 CC was added triethylamine (10.6 mL, 76.0 mmol, 12.0
equiv), Pd(PPh3)4 (366 mg, 0.317 mmol, 5.00 mol%), and formic aid (1.29 mL, 34.2 mmol,
.40 equiv). After stirring for 1 hr at 100 °C, the reaction mixture was cooled to 23 °C and
water (30 mL) and EtOAc (20 mL) was added. The phases were separated and the aqueous
phase was extracted with EtOAc (3 X 20 mL). The combined organic phases were washed
with brine (50 mL) and dried (MgSO4). The filtrate was concentrated in vacuo and the
residue was purified by column chromatography on silica gel eluting with hexanes/EtOAc to
afford 500 mg of the title compound (41% yield).
WO 24302
1H NMR (300 MHz, CDCl3, 23 °C, 5): 10.26 (s, 1H), 9.35 (d, J: 1.2 Hz, 1H), 8.60 (d, J:
1.5 Hz, 1H), 7.97 (dd, J: 10.8 Hz, 7.5 Hz, 1H), 7.97 (dd, J= 9.0 Hz, 8.7 Hz, 1H). 19F NMR
(282 MHz, CDCl3, 23 °C, 5): ~125.3 (m, 1F), —132.3 (m, 1F).
(E)(6,7-diflu0roquinolinyl)(5,6,7,8-tetrahydr0-1,8-naphthyridin
yl)heptenone
o o
H II
N N
\ P\-OMe
I OMe O
/ H
LiCl,DBU N / F
+ N\ /
MeCN l l
/ \
OHC F N F
N F
Under nitrogen, to dimethyl (2—oxo—6-(5,6,7,8—tetrahydro-1,8—naphthyridin—2—
y1)hexy1)phosphonate (599 mg, 1.76 mmol, 1.10 equiv) in MeCN (5 mL) at 23 °C was added
6,7—difluoroquinoline—3-carbaldehyde (310 mg, 1.60 mmol, 1.00 equiv), LiCl (67.8 mg, 1.60
mmol, 1.00 equiv) and DBU (0.251 mL, 1.68 mmol, 1.05 equiv). After stirring for 1 hr at 75
°C, the reaction mixture was cooled to 23 °C and was filtered through a pad of CELITE®.
The filtrate was concentrated in vacuo and the residue was purified by column
tography on silica gel eluting with CH2C12/MeOH to afford 570 mg of the title
compound (84% yield).
1H NMR (300 MHz, CDCl3, 23 °C, 8): 9.07 (d, J: 2.4 Hz, 1H), 8.20 (d, J= 2.1 Hz, 1H), 7.87
(dd, J= 10.8 Hz, 7.5 Hz, 1H), 7.66 (d, J= 16.2 Hz, 1H), 7.62—7.53 (m, 1H), 7.06 (d, J: 7.2
Hz, 1H), 6.93 (d, J: 16.2 Hz, 1H), 6.36 (d, J: 7.2 Hz, 1H), 4.77 (br s, 1H), .38 (m,
2H), 2.79—2.58 (m, 6H), 1.96—1.85 (m, 2H), 1.81—1.69 (m, 4H). 19F NMR (282 MHz, CDCl3,
23 °C, 8): —129.1 (m, 1F), —133.6 (m, 1F).
(E)(6,7-difluoroquinolinyl)(5,6,7,8-tetrahydr0-1,8-naphthyridin
yl)heptenol
O OH
H H
N N / F LiAIH / F
\ /| ”—‘3‘6
| THF N1N\ /1
/ \N /
F \N F
Under en, to (E)- 1 ~(6,7—difluoroquinolin~3-y1)(5,6,7,8—tetrahydro~ 1 ,8—
naphthyridin—2—yl)hept-1—en—3—one (1.03 g, 2.53 mmol, 1.00 equiv) in THF (25 mL) at 0 °C
was added LiAlH4 (1.0 M in THF, 2.53 mL, 2.53 mmol, 1.00 equiv). After ng for 10
min at 0 °C, H20 (96 uL), 15% NaOH aq (96 uL) and H20 (288 uL) were added sequentially
to the reaction mixture. The reaction mixture was warmed to 23 °C and filtered through a
pad of CELITE®. The filtrate was concentrated in vacuo and the residue was purified by
column chromatography on silica gel eluting with CH2Clg/MeOH to afford 780 mg of the title
compound (75% yield).
1H NMR (300 MHz, CDCl3, 23 °C, 5): 8.95 (d, J: 2.4 Hz, 1H), 8.00 (d, J: 2.1 Hz, 1H), 7.81
(dd, J: 10.8 Hz, 7.5 Hz, 1H), 7.52 (d, J= 16.2 Hz, 1H), 7.21 (d, J: 7.2 Hz, 1H), 6.76 (d, J=
16.2 Hz, 1H), 6.48 (dd, J: 16.2 Hz, 4.5 Hz, 1H), 6.34 (d, J: 7.2 Hz, 1H), 4.48—4.42 (m,
1H), 3.47—3.41 (m, 2H), .67 (m, 4H), 1.97~1.47 (m, 8H). 19F NMR (282 MHz, CDCl3,
23 °C, 5): ~132.1 (m, 1F),—135.1 (m, 1F).
3-(6,7-difluoroquinolinyl)(5,6,7,8-tetrahydro-1,8—naphthyridin—2-
yl)nonanoic acid (Compound A6)
1. EtCOzH
0H MeC(OEt)3
ZI 2. H2, Pd/C,
N / F
/ / TFA, MeOH
1 I _——————.
/ \N F 3. NaOH, H20
MeOH
Under nitrogen, to (E)—1—(6,7-difluoroquinolin—3-yl)—7—(5,6,7,8-tetrahydro-1 ,8-
naphthyridin—2—yl)hept—1—enol (780 mg, 1.90 mmol, 1.00 equiv) in MeC(OEt)3 (19 mL) at
23 °C was added EtCOgH (142 uL, 1.90 mmol, 1.00 equiv). After stirring for 2 hr at 140 °C,
the reaction mixture was directly loaded on silica gel and ed by column chromatography
on silica gel eluting with hexanes/EtOAc to afford a crude rearrangement product, which was
used in the next step without further purification.
Under air, to the above obtained residue in MeOH—TFA (10 mL—l mL) at 23 °C was
added 10% Pd/C (127 mg, 0.119 mmol, 6.26 mol%) and H2 was uced with a balloon.
After ng for 1 hr at 23 °C, the on mixture was ed through a pad of CELITE®.
The filtrate was concentrated in vacuo to afford a crude olefin reduction product, which was
used in the next step without further purification.
Under air, to the above obtained residue in MeOH (10 mL) at 23 °C was added 15%
NaOH aq (3.2 mL). After stirring for 20 min at 60 °C, the reaction mixture was neutralized
with 3N HCl and concentrated in vacuo to remove MeOH. The residual aqueous solution
was extracted with EtOAc (3 X 10 mL) and the combined organic phases were washed with
NaHCO3 aq (2 X 5 mL) and dried (MgSO4). The filtrate was concentrated in vacuo and the
residue was purified by column chromatography on silica gel eluting with CH2C12/MeOH to
afford 500 mg of the title compound (58% yield over 3 steps).
1H NMR (300 MHz, CDCl3, 23 °C, 5): 8.79 (s, 1H), 7.97 (s, 1H), .81 (m, 1H), 7.58—
7.47 (m, 1H), 7.24 (d, J= 7.2 Hz, 1H), 6.23 (d, J: 7.2 Hz, 1H), 3.48—3.32 (m, 3H), 2.80—
2.57 (m, 4H), .20 (m, 14H). 19F NMR (282 MHz, CDCl3, 23 °C, 6): —l32.3 (m, 1F), —
135.5 (m, 1F).
Example 7. Synthesis of 9—(5,6,7,8-tetrahydro-1,8—naphthyridin—2-yl)-3—(7-
(trifluoromethyl)quinolin-3—yl)nonanoic acid (Compound A7)
2-chloroiodoquinoline—3-carbaldehyde
i o /
Me N I \l
H Cl N l
Under nitrogen, to POC13 (14.9 mL, 160 mmol, 7.00 equiv) at 0 °C was added DMF
(4.40 mL, 57.1 mmol, 2.50 equiv). After stirring for 10 min at 0 OC, N—(3-
iodopheny1)acetamide (5.96 g, 22.8 mmol, 1.00 equiv; Pialat, A. et al, Org. Lett. 2013,
:1764—1767) was added to the on mixture. After stirring for 17 hr at 75 0C, the
on mixture was poured into iced. The phases were separated and the aqueous phase was
extracted with CH2C12 (3 X 50 mL). The combined organic phases were washed with brine
(100 mL) and dried (MgSO4). The filtrate was concentrated in vacuo and the residue was
purified by column chromatography on silica gel eluting with CH2C12/MeOH to afford 2.9 g
of the title compound (40% yield).
1H NMR (300 MHz, CDC13, 23 °C, 6): 10.55 (s, 1H), 8.72 (s, 1H), 8.52 (s, 1H), 7.93 (dd, J=
8.4 Hz, 1.5 Hz, 1H), 7.69 (d, J= 8.4 Hz, 1H).
2-chloro(trifluoromethyl)quinoline—3-carbaldehyde
OHC FSOZCFZCOZMe 0H0
/ /
| ——-———————> |
\N WP
Cl | CI \N CF3
Under nitrogen, to 2-chloroiodoquinolinecarbaldehyde (2.90 g, 9.13 mmol, 1.00
equiv) in DMF (18 mL) at 23 °C was added CuI (4.35 g, 22.8 mmol, 2.50 equiv) and
2C02Me (11.6 mL, 91.3 mmol, 10.0 equiv). After stirring for 2 hr at 95 °C, the
reaction mixture was cooled to 23 °C and d through a pad of CELITE®. The filtrate
was trated in vacuo and the residue was purified by column chromatography on silica
gel eluting with hexanes/EtOAc to afford 1.5 g of the title compound (63% yield).
1H NMR (300 MHz, CDC13, 23 °C, 6): 10.60 (s, 1H), 8.82 (s, 1H), 8.39 (s, 1H), 8.14 (d, J:
8.4 Hz, 1H), 7.84 (d, J: 8.4 Hz, 1H). 19F NMR (282 MHZ, CDC13, 23 °C, 6): ~63.2 (s, 3F).
7-(trifluoromethyl)quinolinecarbaldehyde
EtSN, HCOZH
0H0 0H0
/ Pd1PPh3)4 /
I ——-———————> l
Cl \N DMF
CF3 \N CFS
Under nitrogen, to 2-chloro(trifluoromethyl)quinolinecarbaldehyde (1.50 g, 5.78
mmol, 1.00 equiv) in DMF (5.8 mL) at 23 °C was added triethylamine (9.67 mL, 69.4 mmol,
12.0 equiv), Pd(PPh3)4 (334 mg, 0.289 mmol, 5.00 mol%), and formic aid (1.18 mL, 31.2
mmol, 5.40 equiv). After stirring for 1 hr at 100 °C, the on e was cooled to 23 °C
and water (30 mL) and EtOAc (20 mL) was added. The phases were separated and the
aqueous phase was ted with EtOAc (3 X 20 mL). The combined organic phases were
washed with brine (50 mL) and dried (MgSO4). The filtrate was concentrated in vacuo and
the residue was purified by column chromatography onsilica gel eluting with s/EtOAc
to afford 412 mg of the title compound (32% yield).
1H NMR (300 MHz, CDCl3, 23 °C, 8): 10.32 (s, 1H), 9.48 (d, J= 1.5 Hz, 1H), 8.71 (d, J:
1.5 Hz, 1H), 8.51 (s, 1H), 8.15 (d, J: 8.4 Hz, 1H), 7.86 (d,J= 8.4 Hz,1H). 19F NMR (282
MHz, CDC13, 23 °C, 8): —63.1 (s, 3F).
(E)(5,6,7,8-tetrahydr0-1,8-naphthyridinyl)(7-(triflu0romethyl)quinolin-
3-yl)heptenone
O O
H II
N N
\ P\-OMe
I OMB O
/ LCI,.l DBU N /
+ N\ /
OHC N CFS
N CF3
Under nitrogen, to yl (2-oxo—6-(5,6,7,8-tetrahydro-1,8-naphthyridin
y1)hexyl)phosphonate (685 mg, 2.01 mmol, 1.10 equiv) in MeCN (9 mL) at 23 °C was added
7-(trifluoromethyl)quinoline-3—carbaldehyde (412 mg, 1.83 mmol, 1.00 equiv), LiCl (77.6
mg, 1.83 mmol, 1.00 equiv) and DBU (0.287 mL, 1.92 mmol, 1.05 equiv). After stirring for
1 hr at 75 °C, the reaction mixture was cooled to 23 °C and was filtered through a pad of
CELITE®. The filtrate was concentrated in vacuo and the residue was purified by column
chromatography on silica gel eluting with CHZClz/MeOH to afford 706 mg of the title
compound (88% yield).
1H NMR (300 MHz, CDC13, 23 °C, 8): 9.19 (d, J: 2.4 Hz, 1H), 8.42 (d, J= 2.1 Hz, 1H), 8.31
(d, J: 2.1 Hz, 1H), 8.00 (d, J= 9.0 Hz, 1H), 7.79 (d, J: 9.0 Hz, 1H), 7.69 (d, J= 16.2 Hz,
1H), 7.04 (d, J= 7.2 Hz, 1H), 6.99 (d, J: 16.2 Hz, 1H), 6.37 (d, J=‘ 7.2 Hz, 1H), 4.78 (br s,
1H), 3.41—3.37 (m, 2H), 2.80—2.58 (m, 6H), 1.93—1.85 (m, 2H), 1.81—1.69 (m, 4H). 19F NMR
(282 MHz, CDC13, 23 °C, 8): —62.8 (s, 3F).
(E)(5,6,7,8-tetrahydr0-1,8-naphthyridinyl)(7-(triflu0r0methyl)quinolin-
3-yl)heptenol
0 OH
H .
. H
N N / LIAIH4 N N\ /
\ / /
| l l I
Under nitrogen, to (E)(5,6,7,8-tetrahydro-1,8-naphthyridin—2-yl)—1-(7-
(trifluoromethyl)quinolin—3—yl)hept-l-en—3-one (705 mg, 1.60 mmol, 1.00 equiv) in THF (16
mL) at 0 °C was added LiAlH4 (1.0 M in THF, 1.60 mL, 1.60 mmol, 1.00 equiv). After
ng for 10 min at 0 °C, H20 (54 uL), 15% NaOH aq (54 uL) and H20 (162 uL) were
added sequentially to the reaction mixture. The reaction mixture was warmed to 23 °C and
filtered through a pad of CELITE®. The filtrate was concentrated in vacuo and the residue
was purified by column chromatography on silica gel eluting with /MeOH to afford
515 mg of the title compound (73% yield).
1H NMR (300 MHz, CDCl3, 23 °C, 8): 9.08 (d, J= 2.4 Hz, 1H), 8.37 (d, J= 2.1 Hz, 1H), 8.08
(d, J: 2.1 Hz, 1H), 7.91 (d, J: 9.0 Hz,1H), 7.71 (d, J: 9.0 Hz, 1H), 7.06 (d, J: 7.2 Hz,
1H), 6.79 (d, J= 16.2 Hz, 1H), 6.53 (dd, J: 16.2 Hz, 4.5 Hz, 1H), 6.34 (d, J= 7.2 Hz, 1H),
4.89 (br s, 1H), .40 (m, 1H), 3.43—3.37 (m, 2H), 2.75—2.57 (m, 4H), .42 (m,
8H). ”P NMR (282 MHz, CDCl3, 23 °C, 5): —62.6 (s, 3F).
9-(5,6,7,8-tetrahydr0-1,8-naphthyridin-Z-yl)(7-(triflu0r0methyl)quinolin
yl)n0nan0ic acid (Compound A7)
1. EtCOZH
OH MeC(0Et)3
ZI 2. H2, Pd/C,
/Z \
\ TFA, MeOH
l |
N CF3 3. NaOH, H20
MeOH
Under nitrogen, to (E)(5 ,6,7,8-tetrahydro— 1 ,8—naphthyridinyl)(7-
(trifluoromethyl)quinolinyl)heptenol (515 mg, 1.17 mmol, 1.00 equiv) in MeC(OEt)3
(12 mL) at 23 °C was added EtCO2H (87.3 uL, 1.17 mmol, 1.00 equiv). After stirring for 2
hr at 140 0C, the reaction mixture was directly loaded on silica gel and purified by column
chromatography on silica gel eluting with hexanes/EtOAc to afford a crude rearrangement
product, which was used in the next step without further ation.
Under air, to the above obtained residue in MeOH—TFA (10 mL—l mL) at 23 °C was
added 10% Pd/C 66.6 mg, 0.0626 mmol, 5.35 mol%) and H2 was introduced with a balloon.
After ng for 1 hr at 23 °C, the reaction mixture was filtered through a pad of CELITE®.
The filtrate was concentrated in vacuo to afford a crude olefin reduction product, which was
used in the next step without further purification.
Under air, to the above obtained e in MeOH (10 mL) at 23 °C was added 15%
NaOH aq (4.4 mL). After stirring for 20 min at 60 °C, the reaction mixture was neutralized
with 3N HCl and concentrated in vacuo to remove MeOH. The residual aqueous solution
was ted with EtOAc (3 X 10 mL) and the combined organic phases were washed with
NaHC03 aq (2 X 5 mL) and dried (MgSO4). The filtrate was concentrated in vacuo and the
residue was purified by column chromatography on silica gel eluting with CHzClz/MeOH to
afford 300 mg of the title compound (53% yield over 3 .
1H NMR (300 MHz, CDC13, 23 °C, 5): 8.93 (s, 1H), 8.40 (s, 1H), 8.03 (s, 1H), 7.91 (d, J:
9.0 Hz, 1H), 7.70 (d, J: 9.0 Hz, 1H), 7.24 (d, J= 7.2 Hz, 1H), 6.23 (d, J: 7.2 Hz, 1H),
3.48—3.40 (m, 3H), 2.80—2.59 (m, 4H), 1.95—1.20 (m, 14H). 19F NMR (282 MHz, CDCl3, 23
°C, 5): ~62.7 (s, 3F).
Example 8. Synthesis of (SD(6-(difluoromethoxy)pyridin—3-yl)(2—oxo—3-((3—((5,6,7,8—
ydro— l ,8-naphthyridin-2—yl)methyl)oxetan—3—yl)methyl)imidazolidin- l —yl)propanoic
acid
The synthetic route is the same as Example 1 except for substituting at Step-8: (3—
7,8—tetrahydro— l ,8-naphthyridin—2-yl)methyl)oxetan-3—yl)methanamine for compound
6b and continuing the synthetic scheme using the same reaction conditions.
Example 9. Synthesis of (53(3—(2,2-difluoro(5,6,7,8-tetrahydro—l,8-naphthyridin-2—
yl)propyl)—2-oxoimidazolidin- l -yl)—3—(6-(difluoromethoxy)pyridin-3 —yl)propanoic acid
OCHF2
o (ZNr o
N N\ NAN¢OH
/ F F \__/
The synthetic route is the same as Example 1 except for tuting at Step-8: 2,2-
difluoro~3-(5,6,7,8-tetrahydro-1,8~naphthyridinyl)propanamine for compound 6b and
continuing the synthetic scheme using the same reaction ions.
The synthesis of 2,2-difluoro(5,6,7,8—tetrahydro-1,8—naphthyridinyl)propan
amine is performed as shown in Scheme 3.
Example 10. sis of (S)(3-(2,2~difluoro(5,6,7,8-tetrahydro-l,8-naphthyridin
yl)propyl)oxoimidazolidinyl)(6~methoxypyridinyl)propanoic acid
O CN=/ O
N |N\ NAN/"$OH
F F \—/
The synthetic scheme is the same as Example 9, except the synthesis in Step 1 uses
sodium 2~chloroacetate instead of sodium 2-chloro-2,2-difluoroacetate. The synthesis
proceeds under the same conditions as Example 3.
e 10-1. Scheme 3
Scheme3
/N NH2
acetone N N NCS N N
I proline \ \ AIBN \ \ CI
\ H ———> | —> |
EtOH / / col4 / /
A B C BuLi
+ ~————>
DMPU
1. propane-1,3-diol
BOW/\NH2 s
BFSOEtz NANHBoc
DE 2. 80020. EtaN
D E
N N N N
\ \ NHBoc Fluorination \ \ NHBoc
l S S ——*———* I
K/l F F
/ / / /
1, H2, Pto2
2, Acid
.......................................
The preparation of intermediates C and E is detailed in the literature and is depicted
above (for C; W02011150156 and for E; Seebach, D. et al., Liebigs Arm. Chem, 1994, 701-
717). The formation of the dianion of E has been described, and it was used to displace
substituted benzylic chlorides (Bradshaw, B. er al., Org. Biomol. Chem, 2008, 6:2138—
2157.). This event similarly affords complex dithiane F. Fluorodesulfiirization of thioketals
has been described with several reagents (Sondej, S. C. et aZ., J. Org. Chem, 1986, 8—
13.); intermediate G is d and deprotected as described in the literature
(US2004003 8963). Fragment H is inserted into the known route to e the target
compounds.
Example 11. Testing of the compounds of present invention in cell adhesion assays
The ability of compounds to block adhesion of three primary cell es: human
dermal microvascular endothelial (HMVEC), rat lung microvascular endothelial (RLMVEC),
and rabbit aortic endothelial (RAEC) cells, to ectin coated plates was determined using
the following ure. This test demonstrates inhibition of the interaction of ow integrin on
the cell surface with the ligand, vitronectin.
Adhesion plates preparation. 96-well plates were coated with vitronectin in PBS,
pH7.4 by ting 50 uL of the solution (10 ug/ml) for 1.5 h at room temperature or
overnight at 4°C. The plates then were blocked with 1% BSA in PBS (30 min at room
temperature) and washed with PBS.
Cell culturing and g. HMVEC cells (passages (p)9-14) (from Lonza,
Allendale, NJ) RLMVEC cells (p4—14) (from Vec Technology, Rensselaer, NY) and RAEC
cells (p4-14) (from CellBiologics, Chicago, IL) were used for the compound testing. Cells
were grown in T175 tissue culture flasks and dislodged by gentle 3 min treatment with
Accutase (Life Technologies). After washing, the cells in suspension in RPMI-1640 (Life
Technologies) were loaded with calcein-AM (5 uM) (Life Technologies) for 30 min at 37 °C
and re-suspended into RPMI w/o phenol red medium containing 10 % FBS.
Adhesion assay. The cell suspension was aliquoted into the wells at a density of
1.0x105 cells/well (RLMVEC) and 5.0x104 (HMVEC, and RAEC). The test compounds are
added at the same time with the cells. The plates are incubated for 1.5 h at 37 °C. The cells
that did not adhere during this incubation were removed by gentle g. The wash was
med by 2 cycles of aspiration of the supernatant and addition of 100 uL of the pre-
warmed fresh DPBS (Life Technologies). A fluorescence of the remaining cells is measured
using multimode plate reader r 2V, Elmer) at an excitation/emission
wavelengths of 485/535 nm. The compounds were tested starting with maximal
tration of 1 uM with half—log dilution schedule. IC50 values were calculated with
Prism 5 (GraphPad, CA) by fixing the bottom of the curves to a value of blank for empty
wells fluorescence.
As shown in Table 2, all the ated (xv antagonists are active in inhibiting cellular
adhesion to vitronectin through the av integrin. orinated reference antagonist, L-
845704, is shown for ison.
Table 2. Potencies of test compounds to block adhesion of different cell cultures to
vitronectin.
IC50 (M)
C("“0“d #
RLMVEC
L-845704
_A5 2.5m 3.7m 2.0E-08
4,413-08 5.5E—09 4.4E—08
A7 1.3E-07 4.0E—07 2.1E—07
Example 12. Anti—angiogenic activity using chick chorioallantoic membrane (CAM) assay
CAM surfaces were grafted with gelatin sponges impregnated with the concentrations
of test compounds and 50 ng VEGF dissolved in PBS. Untreated CAM ed only VEGF
and PBS. Error bars represent SEM, N = 5, P values for the d groups were calculated
by comparing with the untreated group (*p<0.05, **p<0.01, ***p<0.001).
Test Substance ation: Test samples and standards were dissolved in PBS and
sterilized by passing through a syringe filter(0.22 um). hVEGF(SIGMA) 50 ng/ul was
prepared in sterile PBS.
Grafting: n sponge (Abogel) was cut in approximately 2 mm3 pieces and
loaded with required test substance or PBS and VEGF. The graft was placed on the CAM.
Eggs: e hen eggs were procured from a hatchery and were cleaned and
decontaminated using alcohol. 1 ml of albumin was removed using a syringe and incubated
for 8 days. Grafts were placed on developing CAMs and r incubated to day12. On
day12, CAMs were fixed with 4% formaldehyde in PBS, dissected and imaged.
Imaging: Fixed CAMS were imaged under constant illumination and magnification
under a microscope fitted with a digital camera (CANON).
Image analysis: Images were ed on MS PowerPoint keeping the image size
constant. A ring was drawn around the graft and the size was kept constant. Blood vessels
ng the ring were counted for each test group.
Statistical Analysis: Data were analyzed on l 2007.
As shown in Figure 1, Compounds Al and A2 each shows anti-angiogenic activity in
the chick CAM assay, and significantly decreases the number of blood vessels, as compared
to the untreated control.
Example 13. Distribution in plasma, aqueous humor, vitreous humor, and retina after topical
ocular administration in Dutch Belted rabbits
The plasma concentrations and ocular distribution (aqueous humor, vitreous humor,
and retina) of nds Al, A2, and A3 were determined following topical ocular
administration in Dutch Belted rabbits. The test compounds were administered in each eye at
a volume of 50 uL/eye at a concentration of 1.0 - 2.5 mg/mL (compound A2, 1.0 mg/mL;
compounds A1 and A3 at 2.5 mg/mL). Plasma and different ocular tissue samples were
collected at pre-determined time points (1.0 and 8.0 hours for compound A1; 0.5 and 8 hours
for compounds A2 and A3). Aqueous humor, vitreous humor, and retina were ted from
each eye at each time point post-dose. Also, weights were recorded. Plasma and ocular
sample concentrations of the compounds were determined by LC-MS/MS.
Animal Dosing: The exposure of compounds Al, A2, and A3 was ted in Dutch
Belted rabbits. The study was not blinded. Each compound was dosed as n=3/time point for
a total of nine s. Rabbits were housed one per cage. Animals were not fasted, and food
and water were supplied ad libitum.
Animals were anesthetized following the l3lA5 IACUC protocol for the dosing.
Each rabbit ed a bolus dose of test formulation via topical ocular stration into
both eyes at time zero on the day of . Plasma and ocular samples were collected at
pre-determined time points. Animals for the 30-minute and l-hour time points were
anesthetized for the entire duration of the study. The animals for the 8-hour time point were
recovered after dosing and then euthanized for sampling purposes.
At each time point, approximately 0.5 mL of blood was collected and placed into
chilled Na-heparin tubes containing citric acid. Blood samples were centrifuged at a speed of
3,000 g for 5 minutes to obtain plasma as quickly as possible. Samples were stored frozen at
-80°C until is. Animals were euthanized per the l3IA5 IACUC protocol and both eyes
were enucleated immediately. Following enucleation, each eye was rinsed with PBS. Ocular
samples from both eyes of each animal were collected and weights were recorded. All the
samples were frozen immediately on dry ice, and stored at -60 to —80°C for analysis.
Analysis of Plasma and Ocular Samples: An LC—MS/MS method was ped for
the determination of Compounds Al, A2, and A3 in rabbit plasma and ocular samples. A
pre—study standard curve was analyzed to determine the specificity, range, and lower limit of
quantitation of the method.
As shown in Figures 2, 3, and 4, Compounds A1, A2, and A3 are each efficiently
distributed to the retina.
The following examples of ophthalmic formulations are given by way of illustration:
Example 14. Ophthalmic formulation of Compound Al
Solution Cwosition III I
Compound A1 2. 5 g I
B—cyclodextrin sulfobutyl ether 10 g 1200g I
Boric acid 1. 05 g 1. 05 g 1. 05 g I
Disodium orate 0.285 g 0.285 g 2085 g I
I Sodium Chloride 025 g 0.25 g 025 g I
I Edetate um 25 mg 2. 5 mg I 25 mg I
I Propylaminopropyl biguanide 0. 03 mg 0.03 mg I 0.03 mg
I Water for ion q.s. 100 ml 100 ml I 100 ml
The active compounds were addedI to a solution of borate buffered saline containing
the B-cyclodextrin sulfobutyl ether, edetate disodium, and propylamino idate dissolved
in sterile water for ion in a tared sterile vessel. The pH of the on was ed to
7.5 by the addition of hydrochloric acid. The composition is sterilized by filtration through a
0.45 micron filter.
Example 15. Ophthalmic formulation of Compound A1
I Solution Commsition I II III
I 2.5 g I 2.0 I 1.0 “I
I Hyrdoxypropyl B—cyclodextrin I 10 g I 10 g I 5 g
Boric acid I 1.05 g 1.05 g 1.05 g
Disodium tetraborate 0.285 g 0.285 g 0.285 g
Sodium Chloride 0.25 g 0.25 g 025 g__I
Edetate disodium 2.5 mg 2.5 mg I 2. 5 mg
I Propylaminopropyl biguanide 0.03 mg I 0.03 mg
I Water for ion q.s. I 100 ml _I 100 ml I_ 0.03 mg100 ml
The active compounds were added to a solution of borate buffered saline containing
the hydroxylpropyl—B-cyclodextrin, edetate disodium, and amino biguanidate dissolved
in sterile water for injection in a tared sterile vessel. The pH of the solution was adjusted to
7.5 by the addition of hydrochloric acid. The composition is sterilized by filtration through a
0.45 micron filter.
e 16. Ophthalmic formulation of Compound A2
on Com osition
Compound A2 2.0 g 1.5 l
B-cyclodextrin sulfobutyl ether 10 g 10 g i
Boric acid 1.05_L 1.05L l .
Disodium tetraborate 0.285 g I 0.285 g .
Sodium Chloride 0.25 0.25 g .
Edetate disodium 2.5 m 2.5 mg .
l Propylaminopropyl biguanide 0.03 mg 0.03 mg .
1 Water for injection q.s. 100 ml 100 ml
The active compounds were added to a solution of borate buffered saline containing
the B—cyclodextrin sulfobutyl ether, edetate disodium, and propylamino biguanidate dissolved
in sterile water for injection in a tared sterile vessel. The pH of the solution was adjusted to
7.5 by the addition of hydrochloric acid. The composition is sterilized by ion through a
0.45 micron filter.
e 17. Ophthalmic formulation of Compound A3
on Composition I II III
Compound A3 2.5 g 2.0 l 1.0
B—cyclodextrin sulfobutyl ether 10 g 10 g 5 g
Boric acid 1.05 g l.05_g_ 1.05 g
Disodium tetraborate 0.285 g 0.285 g 0.285 g
Sodium Chloride 0.25 g 0.25 g 0.25 g
Edetate disodium 2.5 mg l 2.5 mg i 2.5 mg
Propylaminoplgpyl biguanide 0.03 mg l 0.03 mg i 0.03 mg
Water for injection q.s. 100 ml l 100 ml l 100 ml
The active compounds were added to a solution of borate buffered saline containing
the B-cyclodextrin sulfobutyl ether, edetate disodium, and propylamino biguanidate dissolved
in sterile water for injection in a tared sterile vessel. The pH of the on was adjusted to
7.5 by the addition of hloric acid. The composition is sterilized by filtration through a
0.45 micron filter.
Example 18. Evaluation of the safety and efficacy of topically applied test compounds in the
laser—induced choroidal neovascularization (CNV) model in Dutch Belted rabbits
y male animals weighing between 1.5 and 2.0 kg were used in these studies.
Animals were d prior to dosing and at euthanasia, and more often if needed. Baseline
fundus photography and cein angiography was performed on each animal prior to
CNV induction.
Animals were anesthetized with an intramuscular ion of ketamine hydrochloride
(20 mg/kg) and xylazine (2 mg/kg) for CNV induction, fundus photography, fluorescein
angiography, and itreal (lVT) injections. Rabbits were maintained on ane
(approximatelyl to 3%) in oxygen (approximately 1 to 2 L/min) as necessary. One drop of
topical proparacaine hloride anesthetic (0.5%) was placed in each eye before
procedures. Additional topical ocular esia was utilized during the procedure if needed.
CNV was induced by laser photocoagulation treatment. An external diode laser was
applied to the retina using a laser contact lens and a slit lamp biomicroscope. On Day 1, both
the ing laser
eyes of each animal underwent laser photocoagulation treatment using
settings:
Number of Spots: 12-15 spots per eye
Power Range: 50-200 mW
Spot Size: 20-100 um
Time: 0.05 — 0.1 seconds
ing laser treatment, 50 uL of a 25-ug/mL VEGF solution (1.25 ug dose) was
intraVitreally injected into each eye. Daily gross ocular exams were performed throughout
the study period.
Clinical ophthalmic exams lamp biomicroscopy and indirect ophthalmoscopy),
fundus photography, and fluorescein angiography were performed at baseline and then
weekly for up to 6 weeks post-induction. Exams were scored using the McDonald-Shadduck
Score System. Optical Coherence Tomography OCT imaging was med weekly for
diagnostic imaging during the exams.
On the last day of the study, blood sampling was performed just prior to
administration of the AM dose and at 2 hours post dosing. Blood samples were centrifuged
at a speed of 3,000 g for 5 minutes to obtain plasma as quickly as le. Samples were
stored frozen at -80°C until analysis. At the conclusion of the study, animals were euthanized
per the 13C232Q3 lACUC protocol and both eyes enucleated immediately. Following
enucleation, each eye was rinsed with phosphate-buffered saline. Ocular samples (aqueous
humor, Vitreous humor retina and choroid) from both eyes of each animal were ted and
weights were recorded. All the samples were frozen immediately on dry ice, and stored at -
60 to -80°C for analysis.
As shown in Figure 5, Compound Al or Compound A2 effectively reduced laser-
induced choroidal neovascularization, as compared to the vehicle control.
EQUIVALENTS
Those skilled in the art will ize, or be able to ain using no more than
routine experimentation, many equivalents to the specific embodiments and methods
described herein. Such equivalents are intended to be encompassed by the scope of the
present invention.
All patents, patent applications, and literature references cited herein are hereby
expressly incorporated by reference.
Claims (22)
1. A compound of formula I: (I), or a pharmaceutically able salt or e thereof, wherein: Z is ; R and R’ are each independently H or F, or R and R’, together with the carbon atom to which they are attached, form a 3- or 4-membered carbocyclic or heterocyclic ring; Q is ; X is CH or N; Y is CH or N; R1 is methoxy substituted with 0, 1, 2, or 3 fluorine atoms; and provided that the compound of formula (I) contains at least one fluorine atom.
2. The nd of claim 1, wherein R and R’ are each H.
3. The compound of claim 1, wherein X is N and Y is CH.
4. The compound of claim 1, wherein X and Y are each CH.
5. The compound of claim 1, wherein X and Y are each N.
6. The compound of claim 1, wherein R1 is OCHF2.
7. The compound of claim 1, having formula II: (II), or a pharmaceutically able salt or solvate thereof.
8. The compound of claim 1, selected from the group consisting of: , , , and or a pharmaceutically acceptable salt or solvate thereof.
9. The compound of claim 8, wherein the compound is or a pharmaceutically acceptable salt or e thereof.
10. A compound of formula (I): (I), or a pharmaceutically acceptable salt or solvate thereof, wherein: Z is ; R and R’ are each H; or R and R’, together with the carbon atom to which they are attached, form a 3- or 4-membered carbocyclic or cyclic ring; Q is or ; X is CH or N; Y is CH or N; R1 is C1-C4 alkyl substituted with 1, 2, 3, 4, 5, 6, 7, 8, or 9 fluorine atoms, or C1-C6 alkoxy substituted with 1, 2, 3, 4, 5, 6, or 7 ne atoms; and R2 and R3 are each independently H, F, CH2F, CHF2, or CF3, provided that one of R2 and R3 is not H, provided that the compound of formula (I) contains at least one fluorine atom.
11. The compound of claim 10, wherein R and R’ are each H.
12. The nd of claim 10, wherein Q is , preferably wherein X is N and Y is CH, or preferably wherein X and Y are each CH, or preferably wherein X and Y are each N.
13. The compound of claim 12, wherein R1 is ht chain C1-C4 or branched C3-C4 alkyl, and is substituted with 1, 2, 3, 4, 5, 6, 7, 8, or 9 fluorine atoms, preferably wherein R1 is methyl substituted with 1, 2, or 3 fluorine atoms, more preferably wherein R1 is CF3.
14. The compound of claim 12, wherein R1 is straight chain C1-C6 or branched C3-C6 alkoxy, and is substituted with 1, 2, 3, 4, 5, 6, or 7 fluorine atoms, preferably wherein R1 is methoxy tuted with 1, 2, or 3 fluorine atoms, more preferably wherein R1 is OCHF2.
15. The compound of claim 12, wherein R and R’ are each H; and R1 is methyl tuted with 1, 2, or 3 fluorine atoms or methoxy substituted with 1, 2, or 3 fluorine atoms, preferably wherein X is N and Y is CH and R1 is OCHF2, or wherein X and Y are each N and R1 is CF3.
16. The compound of claim 10, wherein Q is .
17. The compound of claim 10, having formula (II): (II), or a pharmaceutically acceptable salt or solvate thereof.
18. The nd of claim 10, selected from the group consisting of: and , or a pharmaceutically acceptable salt or solvate thereof.
19. The compound of claim 18, selected from the group consisting of: and , or a pharmaceutically able salt or solvate thereof.
20. A pharmaceutical composition comprising a compound ing to any one of the preceding claims or a ceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier or excipient, wherein the pharmaceutical composition optionally comprises a further active ingredient selected from the group consisting of a) an antagonist of integrin α5β1, b) a cytotoxic/antiproliferative agent, c) an inhibitor of epidermal- derived, fibroblast-derived, or et-derived growth factor, d) an inhibitor of VEGF, e) an inhibitor of Flk-1/KDR, Flt-1, Tck/Tie-2, or Tic-1, and f) an inhibitor of oinositide 3- kinase, and a mixture thereof.
21. Use of a compound according to any one of claims 1 to 19 or a pharmaceutically able salt or solvate thereof, optionally in combination with one or more therapies, or a composition according to claim 20 in the manufacture of a medicament for the treatment or prevention of a disease or condition mediated by an αv integrin in a subject.
22. The use according to claim 21, wherein the disease or condition is selected from the group consisting of r degeneration, diabetic retinopathy (DR), macular edema, ic macular edema (DME), and macular edema following retinal vein occlusion (RVO). #59: wocoo mmmmmmmmmmo Time (hr)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361762087P | 2013-02-07 | 2013-02-07 | |
US61/762,087 | 2013-02-07 | ||
US201361900706P | 2013-11-06 | 2013-11-06 | |
US61/900,706 | 2013-11-06 | ||
PCT/US2014/015372 WO2014124302A1 (en) | 2013-02-07 | 2014-02-07 | Fluorinated integrin antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ710447A NZ710447A (en) | 2020-10-30 |
NZ710447B2 true NZ710447B2 (en) | 2021-02-02 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11685737B2 (en) | Fluorinated integrin antagonists | |
CA2976634C (en) | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof | |
JP2022541240A (en) | Boron-containing RHO kinase inhibitor | |
NZ710447B2 (en) | Fluorinated integrin antagonists | |
WO2015175954A1 (en) | Alpha v integrin antagonist compositions | |
US10118929B2 (en) | Nonanoic and decanoic acid derivatives and uses thereof |